Giorgio Walter Canonica

Giorgio Walter Canonica's AcademicInfluence.com Rankings

Philosophy

#3624

World Rank

#5823

Historical Rank

Logic

#1284

World Rank

#1993

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Giorgio Walter Canonica's Degrees

Doctorate Internal Medicine University of Genoa
PhD Immunology University of Genoa

Why Is Giorgio Walter Canonica Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Giorgio Walter Canonica is an Italian allergist, pulmonologist and professor of Respiratory Medicine at Humanitas University, Milan, Italy and Director Personalized Medicine Asthma & Allergy Center at Humanitas Research Hospital IRCCS-Milano Italy since December 2016. He is known for his research work related to innovative treatment strategies for allergic diseases which includes biological response modifier in form of targeted immunotherapy with primary emphasis on sublingual immunotherapy . He has served as Secretary General and President elect of World Allergy Organisation for six consecutive years and has served as president of the same organization during 2007–09. He is also the vice-president of INTERASMA.

(See a Problem?)

Giorgio Walter Canonica's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 * (2008) (3261)
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. (2010) (1448)
The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. (2014) (1106)
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE (2005) (1050)
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision (2017) (1029)
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria (2018) (1014)
Allergen immunotherapy: therapeutic vaccines for allergic diseases (1998) (802)
EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria (2006) (690)
Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report 1 (2011) (617)
Consensus statement * on the treatment of allergic rhinitis (2000) (557)
Practical guide to skin prick tests in allergy to aeroallergens (2012) (532)
Sublingual immunotherapy: World Allergy Organization position paper 2013 update (2014) (496)
EAACI/GA²LEN/EDF/WAO guideline: management of urticaria (2009) (462)
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials (2019) (454)
EAACI/GA2LEN/EDF guideline: management of urticaria (2006) (451)
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (2008) (446)
Sub‐lingual Immunotherapy: World Allergy Organization Position Paper 2009 (2009) (435)
International consensus on allergy immunotherapy. (2015) (427)
Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce (2007) (390)
Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. (1998) (380)
A WAO - ARIA - GA²LEN consensus document on molecular-based allergy diagnostics (2013) (375)
Standards for practical allergen‐specific immunotherapy (2006) (367)
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) (351)
The EAACI/GA 2 LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update (2015) (348)
Long‐lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10‐year prospective study (2003) (333)
Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. (2014) (329)
World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Probiotics (2015) (326)
Antiallergic drugs and the immune response (1989) (324)
GA2LEN skin test study I: GA²LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe (2009) (324)
Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. (2006) (308)
Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. (2007) (295)
Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. (2008) (273)
Noninjection routes for immunotherapy. (2003) (272)
Viruses and bacteria in acute asthma exacerbations – A GA2LEN‐DARE* systematic review (2010) (252)
GA2LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe (2009) (251)
A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU‐Q2oL) (2005) (250)
Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis (1998) (250)
Diagnosis and Rationale for Action Against Cow's Milk Allergy (DRACMA): a summary report. (2010) (244)
Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. (2010) (241)
EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria (2006) (241)
Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. (1995) (236)
A survey of the burden of allergic rhinitis in Europe (2007) (233)
Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. (1999) (225)
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. (2012) (224)
Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. (2014) (221)
Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. (2007) (215)
A survey of the burden of allergic rhinitis in Europe. (2008) (215)
Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. (2008) (211)
Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. (2004) (208)
The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA²LEN meta‐analysis (2009) (203)
Unmet needs in severe chronic upper airway disease (SCUAD). (2009) (200)
International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. (2016) (197)
The nose-lung interaction in allergic rhinitis and asthma: united airways disease (2001) (196)
Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy (2003) (193)
IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts. (1998) (190)
Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. (2019) (188)
The burden of chronic spontaneous urticaria is substantial: Real‐world evidence from ASSURE‐CSU (2017) (187)
GA2LEN/EAACI pocket guide for allergen‐specific immunotherapy for allergic rhinitis and asthma (2010) (186)
Studies on the relationship between the level of specific IgE antibodies and the clinical expression of allergy: I. Definition of levels distinguishing patients with symptomatic from patients with asymptomatic allergy to common aeroallergens. (1995) (182)
Consensus group on new‐generation antihistamines (CONGA): present status and recommendations (2003) (181)
MACVIA‐ARIA Sentinel NetworK for allergic rhinitis (MASK‐rhinitis): the new generation guideline implementation (2015) (178)
Diagnosis and Treatment of Urticaria and Angioedema: A Worldwide Perspective (2012) (178)
Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper (2008) (178)
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial (2021) (167)
Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial. (1999) (165)
The link between allergic rhinitis and asthma: the united airways disease (2010) (164)
A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma (2016) (162)
IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper☆ (2020) (162)
EUFOREA consensus on biologics for CRSwNP with or without asthma (2019) (159)
World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Prebiotics (2016) (158)
Allergic diseases and asthma: a major global health concern. (2012) (157)
Integrated care pathways for airway diseases (AIRWAYS-ICPs) (2014) (155)
Post‐marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years (2005) (154)
Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs (2016) (153)
Rupatadine in allergic rhinitis and chronic urticaria (2008) (151)
Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real‐life: clinical efficacy and more (2004) (149)
The German version of the chronic urticaria quality‐of‐life questionnaire: factor analysis, validation, and initial clinical findings (2009) (149)
Requirements for medications commonly used in the treatment of allergic rhinitis (2003) (148)
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma (2020) (146)
Post‐marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients (1999) (146)
Seasonal and perennial allergic rhinitis: is this classification adherent to real life? (2005) (144)
Pharmacologic and anti‐IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN) (2006) (142)
Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. (1997) (142)
Why do doctors and patients not follow guidelines? (2009) (141)
Climate change, air pollution and extreme events leading to increasing prevalence of allergic respiratory diseases (2013) (139)
Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. (2013) (138)
Allergic rhinitis management pocket reference 2008 * (2008) (138)
Possible role of climate changes in variations in pollen seasons and allergic sensitizations during 27 years. (2010) (136)
Allergic rhinitis (2020) (136)
On the functional consequences of bronchial basement membrane thickening. (2001) (135)
Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. (1998) (135)
Prioritised research agenda for prevention and control of chronic respiratory diseases (2010) (135)
Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. (1995) (132)
Rhinasthma: a new specific QoL questionnaire for patients with rhinitis and asthma (2003) (131)
Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement (2017) (129)
MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. (2016) (128)
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy (2012) (125)
Systemic reactions from skin testing: literature review. (2006) (124)
ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle (2016) (124)
Sub-Lingual Immunotherapy (2009) (124)
Intranasal corticosteroids in allergic rhinitis in COVID‐19 infected patients: An ARIA‐EAACI statement (2020) (124)
Allergic subjects express intercellular adhesion molecule--1 (ICAM-1 or CD54) on epithelial cells of conjunctiva after allergen challenge. (1993) (123)
Allergen-specific challenge induces intercellular adhesion molecule 1 (ICAM-1 or CD54) on nasal epithelial cells in allergic subjects. Relationships with early and late inflammatory phenomena. (1994) (122)
United airways disease: therapeutic aspects (2000) (120)
2019 ARIA Care pathways for allergen immunotherapy (2019) (117)
Interleukin-5 in the Pathophysiology of Severe Asthma (2019) (115)
Unmet needs in asthma: Global Asthma Physician and Patient (GAPP) Survey: global adult findings (2007) (114)
State of World Allergy Report 2008: Allergy and Chronic Respiratory Diseases (2008) (114)
Rhinitis and asthma in athletes: an ARIA document in collaboration with GA2LEN (2006) (113)
Minimal persistent inflammation is also present in patients with seasonal allergic rhinitis. (2000) (110)
GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma ‘epidemic’ (2009) (108)
How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. (2010) (108)
EAACI guidelines on allergen immunotherapy: Executive statement (2018) (108)
Methodology for development of the Allergic Rhinitis and its Impact on Asthma Guideline 2008 update (2007) (108)
Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. (1996) (108)
Recommendations for assessing Patient‐Reported Outcomes and Health‐Related quality of life in clinical trials on allergy: a GA2LEN taskforce position paper (2010) (108)
Important research questions in allergy and related diseases: 3‐chronic rhinosinusitis and nasal polyposis – a GA2LEN study (2009) (107)
Safety of sublingual immunotherapy with monomeric all_ergoid in adults: multicenter post‐marketing surveillance study (2001) (107)
Allergic diseases and their impact on quality of life. (2006) (107)
Safety of sublingual immunotherapy with a monomeric allergoid in very young children (2005) (107)
Omalizumab Modulates Bronchial Reticular Basement Membrane Thickness and Eosinophil Infiltration in Severe Persistent Allergic Asthma Patients (2012) (107)
Allergic Rhinitis and its Impact on Asthma (ARIA): In collaboration with the World Health Organization (2002) (104)
The Severe Asthma Network in Italy: Findings and Perspectives. (2019) (104)
Inhaled and nasal corticosteroids: safety aspects* (2000) (103)
Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. (2007) (103)
The ImmunoCAP ISAC molecular allergology approach in adult multi-sensitized Italian patients with respiratory symptoms. (2011) (103)
Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma. (2018) (103)
Type 2 immunity in asthma (2018) (103)
A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020☆ (2020) (103)
COVID-19: Unanswered questions on immune response and pathogenesis (2020) (102)
Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. (2009) (101)
Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta‐analysis (2011) (100)
Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials (2019) (100)
Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers (2001) (99)
Mechanisms of virus‐induced asthma exacerbations: state‐of‐the‐art. A GA2LEN and InterAirways document (2007) (99)
Increase of asthma and allergic rhinitis prevalence in young Italian men. (1996) (98)
Characterization of severe asthma worldwide: data from the International Severe Asthma Registry (ISAR). (2019) (98)
Uncontrolled allergic rhinitis during treatment and its impact on quality of life: a cluster randomized trial. (2010) (98)
Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis (2013) (98)
A three‐year double‐blind placebo‐controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients (1994) (96)
Is diet partly responsible for differences in COVID-19 death rates between and within countries? (2020) (96)
Is diet partly responsible for differences in COVID-19 death rates between and within countries? (2020) (96)
COVID-19, asthma, and biological therapies: What we need to know (2020) (95)
Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement (2016) (95)
GA2LEN skin test study III: Minimum battery of test inhalent allergens needed in epidemiological studies in patients (2009) (94)
EAACI Biologicals Guidelines—Recommendations for severe asthma (2020) (94)
Severe Chronic Allergic (and Related) Diseases: A Uniform Approach – A MeDALL – GA2LEN – ARIA Position Paper (2012) (93)
Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone. (2016) (93)
Imbalances of T cell subpopulations in patients with atopic diseases and effect of specific immunotherapy. (1979) (93)
Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies (2009) (91)
Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. (2014) (90)
Pilot study of mobile phone technology in allergic rhinitis in European countries: the MASK‐rhinitis study (2017) (90)
Definition, aims, and implementation of GA2LEN Urticaria Centers of Reference and Excellence (2016) (89)
Asthma in the elderly: what we know and what we have yet to know (2014) (89)
Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement (2020) (88)
Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology (2019) (87)
ICAM-1 on epithelial cells in allergic subjects: a hallmark of allergic inflammation. (1995) (87)
MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence (2018) (87)
Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology (2019) (87)
Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. (2014) (87)
The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey (2015) (87)
Evaluation of the nocebo effect during oral challenge in patients with adverse drug reactions. (2004) (86)
Treatment of allergic rhinitis using mobile technology with real‐world data: The MASK observational pilot study (2018) (86)
Evidence of adherence to allergen-specific immunotherapy (2009) (86)
Randomized double‐blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites (2006) (85)
Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. (2005) (85)
The Efficacy and Safety of Cilomilast in COPD (2012) (84)
Recommendations for appropriate sublingual immunotherapy clinical trials. (2009) (83)
Cetirizine reduces ICAM-I on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma. (1996) (82)
How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA‐GA2LEN statement (2011) (82)
Development and implementation of guidelines in allergic rhinitis – an ARIA‐GA2LEN paper (2010) (81)
Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma (2019) (80)
Harmful effect of immunotherapy in children with combined snail and mite allergy. (2002) (80)
Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma (2019) (80)
Recommendations for assessing patient‐reported outcomes and health‐related quality of life in patients with urticaria: a GA2LEN taskforce position paper (2011) (80)
Impact of environmental tobacco smoke and active tobacco smoking on the development and outcomes of asthma and rhinitis (2009) (80)
International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem (2017) (79)
Quantitative assessment of the adherence to sublingual immunotherapy. (2004) (79)
Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry (2019) (79)
SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. (2015) (77)
The clinical safety of H1‐receptor antagonists: An EAACI position paper * (1996) (77)
Allergen immunotherapy on the way to product-based evaluation—a WAO statement (2015) (76)
Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients (2018) (76)
Clinical relevance is associated with allergen-specific wheal size in skin prick testing (2014) (75)
Nasal endoscopy in asthmatic children: assessment of rhinosinusitis and adenoiditis incidence, correlations with cytology and microbiology (2001) (74)
COVID‐19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper (2020) (73)
Adherence to treatment: assessment of an unmet need in asthma. (2006) (73)
Tissue remodelling in upper airways: where is the link with lower airway remodelling? (2006) (73)
Expression of intercellular adhesion molecule‐1 (ICAM‐1) on thyroid epithelial cells in Hashimoto's thyroiditis but not in Graves' disease or papillary thyroid cancer (1991) (72)
Quality of Life in Duchenne Muscular Dystrophy: The Subjective Impact on Children and Parents (2011) (72)
Allergen Immunotherapy (AIT): a prototype of Precision Medicine (2015) (72)
Adhesion molecules of allergic inflammation: recent insights into their functional roles (1994) (72)
Enhancing Respiratory Medication Adherence: The Role of Health Care Professionals and Cost-Effectiveness Considerations. (2016) (72)
Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA2LEN taskforce position paper (2010) (71)
Sublingual immunotherapy for large local reactions caused by honeybee sting: a double-blind, placebo-controlled trial. (2008) (71)
Continuous versus on demand treatment with cetirizine for allergic rhinitis. (1997) (71)
The safety of sublingual immunotherapy with one or multiple pollen allergens in children (2008) (71)
The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy (2013) (71)
The IgE repertoire in children and adolescents resolved at component level: A cross‐sectional study (2012) (70)
World Allergy Organization guidelines for prevention of allergy and allergic asthma. (2004) (70)
Adaptation and validation of the Spanish version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL). (2008) (69)
Work productivity in rhinitis using cell phones: The MASK pilot study (2017) (69)
COVID‐19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments (2020) (69)
Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti‐allergic activity (1997) (69)
International expert consensus on the management of allergic rhinitis (AR) aggravated by air pollutants (2020) (68)
Sublingual immunotherapy for treating allergic conjunctivitis. (2011) (68)
Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines. (1998) (67)
Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. (2006) (67)
Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation. (1995) (67)
Cytokine pattern in allergic and non‐allergic chronic rhinosinusitis in asthmatic children (2002) (67)
Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases (2019) (65)
Perturbations of natural killer cell regulatory functions in respiratory allergic diseases. (2008) (65)
Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis (2013) (64)
A new tool to assess and monitor the burden of chronic cough on quality of life: Chronic Cough Impact Questionnaire (2005) (64)
Characteristics of patients with seasonal allergic rhinitis and concomitant asthma (2004) (64)
Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma (2017) (63)
Evidence of intercellular adhesion molecule-1 expression on nasal epithelial cells in acute rhinoconjunctivitis caused by pollen exposure. (1994) (63)
Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM‐1 expression (1997) (63)
Extended IgE profile based on an allergen macroarray: a novel tool for precision medicine in allergy diagnosis (2018) (63)
Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications (2001) (63)
Development and implementation of guidelines in allergic rhinitis – an ARIA-GA 2 LEN paper (2010) (62)
Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from ASSURE‐CSU (2018) (62)
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma (2020) (62)
Review article: Efficacy of desloratadine in the treatment of allergic rhinitis: a meta‐analysis of randomized, double‐blind, controlled trials (2007) (61)
The role of allergen challenge chambers in the evaluation of anti‐allergic medication: an international consensus paper (2006) (61)
Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe. (2007) (61)
Patient Perceptions of Allergic Rhinitis and Quality of Life: Findings From a Survey Conducted in Europe and the United States (2008) (60)
Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta‐analysis of randomized, double‐blind, placebo‐controlled, clinical trials (2008) (60)
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma (2020) (59)
The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. (2011) (59)
Biomarkers and severe asthma: a critical appraisal (2015) (59)
Nonfatal systemic reactions to subcutaneous immunotherapy: a 10-year experience. (1997) (58)
Efficacy of desloratadine in intermittent allergic rhinitis: a GA2LEN study (2009) (58)
Theophylline and the immune response: in vitro and in vivo effects. (1988) (58)
Terfenadine exerts antiallergic activity reducing ICAM‐1 expression on nasal epithelial cells in patients with pollen allergy (1995) (58)
Long-term cetirizine treatment reduces allergic symptoms and drug prescriptions in children with mite allergy. (2001) (57)
Bronchodilator reversibility in asthma and COPD: findings from three large population studies (2019) (57)
Pharmacokinetics of Der p 2 Allergen and Derived Monomeric Allergoid in Allergic Volunteers (2005) (57)
Pharmacovigilance of drug allergy and hypersensitivity using the ENDA–DAHD database and the GA2LEN platform. The Galenda project (2009) (57)
ARIA‐suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN Review (2008) (57)
An update on the asthma-rhinitis link (2004) (57)
The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine (2004) (56)
SQ HDM SLIT-tablet (ALK) in treatment of asthma--post hoc results from a randomised trial. (2014) (56)
One year of mepolizumab. Efficacy and safety in real-life in Italy. (2019) (55)
ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020) (2020) (55)
Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis (2020) (55)
Bilastine: new insight into antihistamine treatment (2015) (55)
IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies. (2017) (55)
Update on rupatadine in the management of allergic disorders (2015) (54)
Administration regimens for sublingual immunotherapy to pollen allergens: What do we know? (2009) (54)
The natural history of respiratory allergy: a follow-up study of 99 patients up to 10 years. (2001) (54)
Treating asthma as an inflammatory disease. (2006) (54)
Electronic Clinical Decision Support System for allergic rhinitis management: MASK e‐CDSS (2018) (54)
Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity (1997) (54)
Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. (2009) (54)
Clara cell 16 protein in COPD sputum: a marker of small airways damage? (2007) (53)
Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. (2008) (53)
Asthma: personalized and precision medicine (2017) (53)
ARIA‐EAACI statement on severe allergic reactions to COVID‐19 vaccines – An EAACI‐ARIA Position Paper (2020) (53)
Efficacy of Desloratadine in Persistent Allergic Rhinitis – A GA2LEN Study (2010) (53)
The CONSORT statement checklist in allergen‐specific immunotherapy: a GA2LEN paper (2009) (52)
Continuous antihistamine treatment controls allergic inflammation and reduces respiratory morbidity in children with mite allergy (1999) (52)
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. (2020) (52)
Effects of H1 antihistamines on adhesion molecules: a possible rationale for long‐term treatment (1999) (52)
Inflammatory and mechanical factors of allergen-induced bronchoconstriction in mild asthma and rhinitis. (2001) (52)
ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria (2015) (52)
Functionally relevant decreases in activatory receptor expression on NK cells are associated with pulmonary tuberculosis in vivo and persist after successful treatment. (2009) (52)
Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA (2016) (52)
Psychological aspects in asthma: do psychological factors affect asthma management? (2015) (51)
Specific immunotherapy in asthma: efficacy and safety (2011) (51)
Antihistaminic, Anti-Inflammatory, and Antiallergic Properties of the Nonsedating Second-Generation Antihistamine Desloratadine: A Review of the Evidence (2011) (51)
Impact of chronic urticaria on the quality of life of patients followed up at a university hospital * (2016) (51)
Efficacy and safety of sublingual immunotherapy. (2004) (51)
Fexofenadine reduces nasal congestion in perennial allergic rhinitis (2001) (51)
Circulating T lymphocytes in Hashimoto's disease: imbalance of subsets and presence of activated cells. (1982) (51)
The role of patient training in the management of seasonal rhinitis and asthma: clinical implications (2001) (50)
Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters (2006) (50)
A Charter to Improve Patient Care in Severe Asthma (2018) (50)
Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma (2018) (50)
Focus on Cat Allergen (Fel d 1): Immunological and Aerodynamic Characteristics, Modality of Airway Sensitization and Avoidance Strategies (2003) (49)
Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months (2017) (49)
Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5) (2016) (49)
Ocular challenge and hyperresponsiveness to histamine in patients with allergic conjunctivitis. (1993) (49)
Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. (2006) (49)
Turkish version of the chronic urticaria quality of life questionnaire: cultural adaptation, assessment of reliability and validity. (2012) (48)
Intercellular adhesion molecule‐1 on cultured human epithelial cell lines: influence of proinflammatory cytokines (1997) (48)
Receptors for Immunoglobulins on Resting and Activated Human T Cells (1981) (48)
When Allergic Rhinitis is not Only Allergic (2009) (48)
Does asthma control correlate with quality of life related to upper and lower airways? A real life study (2009) (47)
Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules. (2003) (47)
Does a ‘reverse’ atopic march exist? (2008) (47)
Allergic reactions to honey and royal jelly and their relationship with sensitization to compositae. (1998) (47)
Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections (2007) (47)
Local immunotherapy (1998) (47)
Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: a meta‐analysis (2011) (46)
Impact of rhinitis on airway inflammation: biological and therapeutic implications (2001) (46)
The international survey on the management of allergic rhinitis by physicians and patients (ISMAR) (2012) (46)
Lung myofibroblasts as targets of salmeterol and fluticasone propionate : inhibition of α-SMA and NF-κB (2005) (46)
Antibiotic Treatment of Severe Exacerbations of Chronic Obstructive Pulmonary Disease with Procalcitonin: A Randomized Noninferiority Trial (2015) (45)
Seasonal rhinitis and azelastine: long- or short-term treatment? (1997) (45)
Protective effect of loratadine on late phase reaction induced by conjunctival provocation test. (1993) (44)
Treatment of acquired cold urticaria with cetirizine and zafirlukast in combination. (2003) (44)
Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma: A Delphi Study. (2020) (44)
World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Vitamin D (2016) (44)
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines (2021) (44)
Role of contact sensitization in chronic urticaria. (2007) (44)
Therapeutic interventions in severe asthma (2016) (43)
Asthma mortality, inhaled steroids, and changing asthma therapy in Argentina (1990-1999). (2006) (43)
Sleep disturbances and asthma control: a real life study. (2009) (43)
Cetirizine treatment of allergic cough in children with pollen allergy (1997) (43)
Characteristics and treatment regimens across ERS SHARP severe asthma registries (2019) (43)
Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies (2020) (42)
The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group (2019) (42)
Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry. (2020) (42)
The type of sensitizing allergen can affect the evolution of respiratory allergy (2006) (42)
Sublingual immunotherapy: an update (2004) (42)
Bridging allergologic and botanical knowledge in seasonal allergy: a role for phenology. (2010) (42)
Pidotimod: the state of art (2015) (42)
Personalized Medicine in Allergy (2016) (42)
ARIA guideline 2019: treatment of allergic rhinitis in the German health system (2019) (41)
Sublingual immunotherapy for Alternaria-induced allergic rhinitis: a randomized placebo-controlled trial. (2010) (41)
Eosinophilic and non-eosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. (2021) (41)
Is sensitization to furry animals an independent allergic phenotype in nonoccupationally exposed individuals? (2011) (41)
Long‐term follow‐up of nasal immunotherapy to Parietaria: clinical and local immunological effects (1997) (41)
Prophylactic management of children at risk for recurrent upper respiratory infections: the Preventia I Study (2004) (41)
Phenotypic and functional analysis at the clonal level of infiltrating T lymphocytes in papillary carcinoma of the thyroid: prevalence of cytolytic T cells with natural killer-like or lymphokine-activated killer activity. (1989) (40)
Minimal clinically important difference for asthma endpoints: an expert consensus report (2020) (40)
Asthma treatment: ‘magic bullets which seek their own targets’ (2007) (40)
The impact of GINA suggested drugs for the treatment of asthma on Health‐Related Quality of Life: a GA2LEN review (2008) (40)
Controlled study of preseasonal immunotherapy with grass pollen extract in tablets: effect on bronchial hyperreactivity. (2001) (40)
Protective effect of loratadine on specific conjunctival provocation test. (1991) (39)
A double‐blind, placebo‐controlled study on the diagnostic accuracy of an electrodermal test in allergic subjects (2002) (39)
Adaptation and initial results of the Polish version of the GA(2)LEN chronic urticaria quality of life questionnaire (CU-Q(2)oL). (2011) (39)
Feasibility and validation of telespirometry in general practice: The Italian "Alliance" study. (2009) (39)
Omalizumab chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response. (2018) (39)
/ GA 2 LEN / EDF / WAO guideline for the definition , classification , diagnosis and management of urticaria (2018) (38)
Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study. (2019) (38)
Allergen Immunotherapy: History and Future Developments. (2016) (38)
INTERLEUKIN (IL)-4 AND IL-13 ACT ON HUMAN LUNG FIBRO-BLAST (1998) (38)
CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report (2017) (38)
Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review (2012) (38)
Evidences of efficacy of allergen immunotherapy in atopic dermatitis: an updated review (2012) (37)
Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing. (2004) (37)
SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma (2017) (37)
Clonal analysis of T lymphocytes infiltrating the thyroid gland in Hashimoto's thyroiditis. (1987) (37)
COVID-19 mortality rates in the European Union, Switzerland, and the UK: effect of timeliness, lockdown rigidity, and population density. (2020) (37)
Anaphylaxis to sesame (2000) (37)
Sleep disturbances in allergic diseases (2006) (37)
Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly (2015) (37)
Defect of autologous mixed lymphocyte reaction and interleukin-2 in aged individuals (1985) (37)
ALLERGY Net: The safety of sublingual immunotherapy with one or more allergens in adults (2008) (36)
Disability in COPD and its relationship to clinical and patient-reported outcomes (2011) (36)
High mortality in COVID‐19 patients with mild respiratory disease (2020) (36)
New insights into airway remodelling in asthma and its possible modulation (2008) (36)
Systematic Review on the Efficacy of Fexofenadine in Seasonal Allergic Rhinitis: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Clinical Trials (2011) (36)
CD40 on Adult Human Airway Epithelial Cells: Expression and Proinflammatory Effects1 (2004) (35)
Effects of conjunctival hyperosmolar challenge in allergic subjects and normal controls. (1994) (35)
Thyroglobulin-induced T-cell in vitro proliferation in Hashimoto's thyroiditis: identification of the responsive subset and effect of monoclonal antibodies directed to Ia antigens. (1984) (35)
Intranasal mometasone furoate reduces late-phase inflammation after allergen challenge. (2001) (35)
Switching treatments in COPD: implications for costs and treatment adherence (2015) (35)
The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials (2018) (35)
Sublingual immunotherapy in the treatment of adult allergic rhinitis patients (2006) (35)
Sex in Respiratory and Skin Allergies (2019) (35)
Medical treatment reverses cytokine pattern in allergic and nonallergic chronic rhinosinusitis in asthmatic children (2003) (35)
Long‐lasting clinical efficacy of allergen specific immunotherapy (2002) (35)
Local Side Effects of Sublingual and Oral Immunotherapy. (2017) (35)
Effects of mometasone furoate on the quality of life: a randomized placebo‐controlled trial in persistent allergic rhinitis and intermittent asthma using the Rhinasthma questionnaire (2011) (35)
Debates in allergy medicine: Molecular allergy diagnosis with ISAC will replace screenings by skin prick test in the future (2017) (35)
Protective effect of different doses of terfenadine on the conjunctival provocation test (1992) (34)
Erratum: asthma in the elderly: what we know and what we have yet to know (2014) (34)
Sublingual swallow or spit? (2001) (34)
ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice (2020) (34)
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine? (2017) (34)
ARIA pharmacy 2018 “Allergic rhinitis care pathways for community pharmacy” (2019) (34)
Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions (2015) (34)
The impact of allergic rhinitis on quality of life and other airway diseases. Summary of a European conference. (1998) (34)
Loratadine in the treatment of cough associated with allergic rhinoconjunctivitis. (1995) (34)
Adherence to asthma treatments: ‘we know, we intend, we advocate’ (2015) (33)
Gender differences in asthma perception and its impact on quality of life: a post hoc analysis of the PROXIMA (Patient Reported Outcomes and Xolair® In the Management of Asthma) study (2019) (33)
Topical ocular levocabastine reduces ICAM‐1 expression on epithelial cells both in vivo and in vitro (1996) (33)
360 degree perspective on allergic rhinitis management in Italy: a survey of GPs, pharmacists and patients (2015) (33)
Lower airway inflammation before and after house dust mite nasal challenge: an age and allergen exposure-related phenomenon. (2007) (33)
Latex immunotherapy: state of the art. (2012) (33)
An update on allergen immunotherapy and asthma (2014) (33)
Gender differences in asthma perception and its impact on quality of life: a post hoc analysis of the PROXIMA (Patient Reported Outcomes and Xolair® In the Management of Asthma) study (2019) (33)
Allergen-Specific Nasal Challenge: Response Kinetics of Clinical and Inflammatory Events to Rechallenge (1998) (33)
Unsatisfactory asthma control: astonishing evidence from general practitioners and respiratory medicine specialists. (2010) (33)
Proliferation of T8-positive cytolytic T lymphocytes in response to thyroglobulin in human autoimmune thyroiditis: analysis of cell interactions and culture requirements. (1985) (33)
30 years of sublingual immunotherapy (2019) (33)
Asthma exacerbation in children: relationship among pollens, weather, and air pollution. (2014) (33)
Efficacy of Mometasone Furoate Nasal Spray in the Treatment of Allergic Rhinitis: Meta-analysis of Randomized, Double-blind, Placebo-controlled Clinical Trials (2008) (33)
From "blockbusters" to "biosimilars": an opportunity for patients, medical specialists and health care providers. (2012) (32)
Office spirometry can improve the diagnosis of obstructive airway disease in primary care setting. (2009) (32)
Sensitization to Horse Allergens in Italy: A Multicentre Study in Urban Atopic Subjects without Occupational Exposure (2011) (32)
Anti‐proliferative and anti‐remodelling effect of beclomethasone dipropionate, formoterol and salbutamol alone or in combination in primary human bronchial fibroblasts (2008) (32)
RhinAsthma Patient Perspective: a short daily asthma and rhinitis QoL assessment (2012) (32)
Comparison of the Effects in the Nose and Skin of a Single Dose of Desloratadine and Levocetirizine over 24 Hours (2004) (32)
Targeted therapy in severe asthma today: focus on immunoglobulin E (2017) (32)
Four-year follow-up in children with moderate/severe uncontrolled asthma after withdrawal of a 1-year omalizumab treatment (2015) (32)
Safety and tolerability of sublingual immunotherapy in clinical trials and real life (2013) (31)
Psychometric evaluation of Global Evaluation of Treatment Effectiveness: a tool to assess patients with moderate-to-severe allergic asthma (2007) (31)
The Seven Stages of Man: The Role of Developmental Stage on Medication Adherence in Respiratory Diseases. (2016) (31)
Lung myofibroblasts as targets of salmeterol and fluticasone propionate: inhibition of alpha-SMA and NF-kappaB. (2005) (31)
Topical azelastine in perennial allergic conjunctivitis (2003) (31)
Disease-modifying effect and economic implications of sublingual immunotherapy. (2011) (31)
The safety of allergen specific sublingual immunotherapy. (2007) (31)
Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps (2015) (30)
Allergic diseases in the elderly: biological characteristics and main immunological and non-immunological mechanisms (2017) (30)
The nocebo effect during oral challenge in subjects with adverse drug reactions. (2008) (30)
Cross‐cultural adaptation of the Brazilian–Portuguese version of the chronic urticaria quality‐of‐life questionnaire – CU‐Q2oL (2011) (30)
Introduction to nasal and pulmonary allergy cascade (2002) (29)
Treatment strategies for asthma: reshaping the concept of asthma management (2020) (29)
The possible influence of the environment on respiratory allergy: a survey on immigrants to Italy. (2011) (29)
Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma? (2016) (29)
Fatal asthma; is it still an epidemic? (2016) (29)
A multicentric study on sensitivity and specificity of a new in vitro test for measurement of IgE antibodies. (1991) (29)
Anaphylaxis caused by skin prick testing with aeroallergens: Case report and evaluation of the risk in Italian allergy services. (2003) (29)
Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model (2020) (29)
Sublingual or injection immunotherapy: the final answer? (2004) (29)
Graves' disease: phenotypic and functional analysis at the clonal level of the T-cell repertoire in peripheral blood and in thyroid. (1988) (29)
Sublingual immunotherapy: update 2006 (2006) (29)
Systemic reactions to peach are associated with high levels of specific IgE to Pru p 3 (2009) (29)
Beta₂-agonists for exercise-induced asthma. (2013) (28)
Human lung myofibroblasts as effectors of the inflammatory process: the common receptor γ chain is induced by Th2 cytokines, and CD40 ligand is induced by lipopolysaccharide, thrombin and TNF‐α (2002) (28)
Drug treatment of allergic conjunctivitis. A review of the evidence. (1992) (28)
Advanced forecasting of SARS‐CoV‐2‐related deaths in Italy, Germany, Spain, and New York State (2020) (28)
The added value of allergen microarray technique to the management of poly-sensitized allergic patients (2012) (28)
Allergenius, an expert system for the interpretation of allergen microarray results (2014) (28)
Airborne pollens and prevalence of pollenosis in western Liguria: a 10-year study. (1999) (28)
The evolving algorithm of biological selection in severe asthma (2020) (28)
Component-resolved diagnosis in pediatric allergic rhinoconjunctivitis and asthma (2013) (28)
Asthma from immune pathogenesis to precision medicine. (2019) (28)
Asthma and COPD: Interchangeable use of inhalers. A document of Italian Society of Allergy, Asthma and Clinical Immmunology (SIAAIC) & Italian Society of Respiratory Medicine (SIMeR). (2015) (28)
Is allergic sensitization relevant in severe asthma? Which allergens may be culprit? (2017) (28)
Cutting Edge: Biomarkers for Chronic Spontaneous Urticaria (2018) (27)
Validation of the Global Allergy and Asthma European Network (GA2LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber (2017) (27)
An academic allergy unit during COVID-19 pandemic in Italy (2020) (27)
Performance evaluation of ImmunoCAP® ISAC 112: a multi-site study (2017) (27)
Circulating T-cell subsets in Graves' disease: differences between patients with active disease and in remission after 131I-therapy. (1983) (27)
Immunostimulants in respiratory diseases: focus on Pidotimod (2019) (27)
Pharmacotherapy of allergic rhinitis: current options and future perspectives (2014) (27)
Levocabastine versus cromolyn sodium in the treatment of pollen-induced conjunctivitis. (1990) (27)
Rhinitis, rhinosinusitis and quality of life in children (2007) (27)
AIT (allergen immunotherapy): a model for the “precision medicine” (2015) (27)
The Clinical Characteristics of Respiratory Allergy in Immigrants in Northern Italy (2008) (26)
Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma (2016) (26)
Airway remodelling in children: when does it start? (2007) (26)
Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis (2013) (26)
Sublingual immunotherapy for allergic rhinitis and conjunctivitis. (2013) (26)
New oral H1 antihistamines in children: facts and unmeet needs (2008) (26)
International Severe Asthma Registry: Mission Statement: The ISAR Study Group. (2019) (26)
Oxatomide reduces inflammatory events induced by allergen-specific conjunctival challenge. (1995) (26)
Summary of the conclusions (1999) (26)
The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management☆ (2021) (26)
The Effect of Intranasal Corticosteroids on Asthma Control and Quality of Life in Allergic Rhinitis with Mild Asthma (2011) (26)
Asthma Management Failure: A Flaw in Physicians' Behavior or in Patients' Knowledge? (2011) (26)
Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19 (2021) (25)
Face masks, respiratory patients and COVID-19 (2020) (25)
Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry (ISAR). (2021) (25)
Sublingual Immunotherapy: Clinical Indications in the WAO-SLIT Position Paper (2010) (25)
CD4+CD25highCD127- regulatory T-cells in COPD: smoke and drugs effect (2016) (25)
Strategies to reduce corticosteroid-related adverse events in asthma (2019) (25)
Underdiagnosis and Undertreatment of Asthma: A 9-Year Study of Italian Conscripts (2001) (25)
Obstructive lung diseases and inhaler treatment: results from a national public pragmatic survey (2013) (25)
Distinct regulation of HLA class II and class I cell surface expression in the THP‐1 macrophage cell line after bacterial phagocytosis (1999) (25)
Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. (2012) (25)
Structure and classification of H1-antihistamines and overview of their activities. (2002) (25)
The role of interleukin 5 in asthma (2016) (25)
Immunological mechanisms underlying chronic rhinosinusitis with nasal polyps (2018) (25)
Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study (2018) (25)
Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience (2016) (24)
Patient knowledge, perceptions, expectations and satisfaction on allergen-specific immunotherapy: a survey. (2013) (24)
Impact of Bariatric Surgery on Pulmonary Function and Nitric Oxide in Asthmatic and Non-Asthmatic Obese Patients (2011) (24)
Deflazacort protects against late‐phase but not early‐phase reactions induced by the allergen‐specific conjunctival provocation test (1993) (24)
Microarray evaluation of specific IgE to allergen components in elite athletes (2012) (24)
ARIA guideline 2019: treatment of allergic rhinitis in the German health system. (2019) (24)
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) (2020) (24)
WHY THYROID IS MAJOR SITE OF THYROID AUTOANTIBODY SYNTHESIS IN AUTOIMMUNE THYROID DISEASE (1983) (24)
The Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) ERS Clinical Research Collaboration: a new dawn in asthma research (2018) (24)
Local allergic rhinitis: entopy or spontaneous response? (2016) (24)
Selecting optimal second-generation antihistamines for allergic rhinitis and urticaria in Asia (2017) (23)
The role of Pneumococcal vaccine. (2008) (23)
Prescriptive adherence to GINA guidelines and asthma control: An Italian cross sectional study in general practice. (2019) (23)
Severe respiratory allergy induced by indirect exposure to rabbit dander: a case report (2004) (23)
A review of the evidence from comparative studies of levocetirizine and desloratadine for the symptoms of allergic rhinitis. (2005) (23)
General strategy for the management of bronchial asthma in pregnancy. (2003) (23)
Sensitization profiles in polysensitized patients from a restricted geographical area: further lessons from multiplexed component resolved diagnosis. (2011) (23)
Chronic cough and QoL in allergic and respiratory diseases measured by a new specific validated tool-CCIQ. (2006) (23)
Human T-lymphocyte subpopulations in Hashimoto's disease. (1981) (23)
Randomized open comparison of montelukast and sublingual immunotherapy as add-on treatment in moderate persistent asthma due to birch pollen. (2010) (23)
Clinical and cytologic characteristics of allergic rhinitis in elderly patients. (2012) (23)
Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study (2019) (23)
A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress (2015) (23)
Guideline recommendations on the use of allergen immunotherapy in house dust mite allergy: Time for a change? (2017) (22)
Pitfalls in Respiratory Allergy Management: Alexithymia and Its Impact on Patient-Reported Outcomes (2011) (22)
Quality of life and polysensitization in young men with intermittent asthma. (2005) (22)
The relationship between mucosal immunoresponse and clinical outcome in patients with recurrent upper respiratory tract infections treated with a mechanical bacterial lysate. (2011) (22)
Adherence to sublingual immunotherapy: the allergists' viewpoint (2009) (22)
Seeking allergy when it hides: which are the best fitting tests? (2013) (22)
T lymphocyte subpopulations in Graves' disease: relationship with clinical conditions. (1983) (22)
Immunotherapy: clinical trials – optimal trial and clinical outcomes (2007) (22)
Novel Anti-inflammatory Effects of the Inhaled Corticosteroid Fluticasone Propionate During Lung Myofibroblastic Differentiation1 (2001) (22)
Pharmacokinetics of radiolabelled Par j 1 administered intranasally to allergic and healthy subjects (2005) (22)
Current insights in allergen immunotherapy. (2018) (22)
RHINASTHMA‐Adolescents: a new quality of life tool for patients with respiratory allergy (2014) (22)
The patient with rhinitis in the pharmacy. A cross-sectional study in real life (2015) (22)
Biomarker discovery in asthma and COPD by proteomic approaches (2014) (22)
Local immunotherapy: pharmacokinetics and efficacy (1998) (22)
Allergen immunotherapy: The growing role of observational and randomized trial “Real‐World Evidence” (2021) (22)
In vitro effects of Bacillus subtilis on the immune response. (1986) (22)
Local Nasal Specific Immunotherapy for Allergic Rhinitis (2006) (22)
New Therapies for Allergic Rhinitis (2014) (22)
Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. (2010) (22)
Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety (2015) (21)
GAPP SURVEY WORKING GROUP. UNMET NEEDS IN ASTHMA: GLOBAL PHYSICIAN AND PATIENT (GAPP) SURVEY: GLOBAL ADULT FINDINGS (2007) (21)
Sedation from H1 antagonists: evaluation methods and experimental results. (1993) (21)
Effects on symptoms and quality of life of hypertonic saline nasal spray added to antihistamine in persistent allergic rhinitis--a randomized controlled study. (2005) (21)
Follicular thyroid cells of autoimmune thyroiditis may coexpress ICAM-1 (CD54) and its natural ligand LFA-1 (CD11a/CD18). (1995) (21)
Patients with Asthma and Comorbid Allergic Rhinitis: Is Optimal Quality of Life Achievable in Real Life? (2011) (21)
The relationship between allergen immunotherapy and omalizumab for treating asthma (2015) (21)
Quantitative flow cytometric analysis of the effects of cetirizine on the expression of ICAM‐1/CD54 on primary cultured nasal cells (2000) (21)
Lack of neo-sensitization to Pen a 1 in patients treated with mite sublingual immunotherapy (2010) (21)
Evidence of the efficacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial (2017) (21)
Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal anti-inflammatory drugs. (2003) (21)
Modulation of airway caliber by deep inhalation in children. (2000) (21)
Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre, double-blind, randomised, controlled, phase IV study (AIACE st (2015) (20)
Successful SARS-CoV-2 vaccine allergy risk-management: The experience of a large Italian University Hospital☆ (2021) (20)
Non-injection routes for immunotherapy of allergic diseases. (2004) (20)
Oral and sublingual immunotherapy in paediatric patients (2003) (20)
Molecular diagnosis and precision medicine in allergy management (2016) (20)
Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis (2021) (20)
In situ hybridization analysis of ICAM‐1 (CD54) mRNA on conjunctival epithelium during allergic inflammation (1997) (20)
Antihistamines: do they work? Further well‐controlled trials involving larger samples are needed (2004) (20)
Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies (2016) (20)
Loratadine reduces the expression of ICAM‐1 (1998) (20)
Sublingual Immunotherapy: Recent Advances. (2013) (20)
Autoimmune thyroid disease: purification and phenotypic analysis of intrathyroid T cells (1984) (19)
Allergy clinics in times of the SARS-CoV-2 pandemic: an integrated model (2020) (19)
International severe asthma registry (ISAR): protocol for a global registry (2019) (19)
Randomized open comparison of the safety of SLIT in a no-updosing and traditional updosing schedule in patients with Parietaria allergy. (2006) (19)
Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: Effects on circulating T, B and NK cells. (2013) (19)
Emerging drugs for allergic conjunctivitis (2014) (19)
Genuair® Usability Test: Results of a National Public Survey of the Elderly (2016) (19)
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations (2017) (19)
Sublingual immunotherapy in pediatric patients: beyond clinical efficacy (2005) (19)
Sleep Apnea Risk in Subjects With Asthma With or Without Comorbid Rhinitis (2014) (19)
Effective long-term α-interferon treatment for hypereosinophilic syndrome (1995) (19)
The administration of a polyvalent mechanical bacterial lysate in elderly patients with COPD results in serological signs of an efficient immune response associated with a reduced number of acute episodes. (2014) (19)
Evidence of desloratadine syrup efficacy and tolerability in children with pollen‐induced allergic rhinitis (2005) (19)
Critical appraisal of the unmet needs in the treatment of chronic spontaneous urticaria with omalizumab: an Italian perspective (2017) (19)
Adjustable maintenance dosing: suitability of budesonide/formoterol in a single inhaler and overview of a clinical study programme (2004) (18)
Real-life studies of biologics used in asthma patients: key differences and similarities to trials (2019) (18)
Quality‐of‐life issues in survivors to anaphylactic reactions to drugs (2015) (18)
Unconventional medicine: a risk of undertreatment of allergic patients (1999) (18)
Sublingual immunotherapy: certainties, unmet needs and future directions. (2009) (18)
Efficacy of dupilumab in atopic comorbidities associated with moderate‐to‐severe adult atopic dermatitis (2020) (18)
Long-acting bronchodilators improve health related quality of life in patients with COPD. (2013) (18)
Allergy training and immunotherapy in Latin America: results of a regional overview. (2013) (18)
Sublingual immunotherapy: other indications. (2011) (18)
Quality of sleep in allergic children and their parents. (2015) (18)
Aspirin challenge/desensitisation before coronary stenting in subjects with history of hypersensitivity. A pragmatic approach. (2012) (18)
Minimal persistent inflammation may be controlled by cetirizine. (1999) (18)
Treating the allergic patient: think globally, treat globally (2002) (18)
Treating Moderate-to-Severe Allergic Asthma with a Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab) (2006) (18)
Immunopathological features of air pollution and its impact on inflammatory airway diseases (IAD) (2020) (17)
Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype (2017) (17)
Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10 (2012) (17)
Molecular events in allergic inflammation: experimental models and possible modulation (1997) (17)
Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI (2020) (17)
T cell activation through different membrane structures (T3/Ti, T11, T44) and frequency analysis of proliferating and interleukin-2 producer T lymphocyte precursors in aged individuals (1988) (17)
Inhibitory effect of an antibody against alpha 1-acid glycoprotein (alpha 1-AGP) on autologous mixed lymphocyte reaction and anti-T3 T-lymphocyte activation. (1986) (17)
May We Strengthen the Human Natural Defenses with Bacterial Lysates? (2010) (17)
The perception of allergen-specific immunotherapy among pediatricians in the primary care setting (2015) (17)
Levocetirizine in persistent allergic rhinitis: continuous or on-demand use? A pilot study (2008) (17)
Illness perception, mood and coping strategies in allergic rhinitis: are there differences among ARIA classes of severity? (2014) (17)
ICAM‐1/CD54 expression on conjunctival epithelium during pollen season (1995) (17)
Development and validation of combined symptom‐medication scores for allergic rhinitis * (2021) (17)
Urticaria: recommendations from the Italian Society of Allergology, Asthma and Clinical Immunology and the Italian Society of Allergological, Occupational and Environmental Dermatology (2020) (16)
Cross‐sectional comparison of the characteristics of respiratory allergy in immigrants and Italian children (2014) (16)
Aeropollinic sampling at three different heights by personal volumetric collector (Partrap FA 52) (1999) (16)
Manifesto on united airways diseases (UAD): an Interasma (global asthma association – GAA) document (2021) (16)
Inhibition of adhesion molecules by budesonide on a human epithelial cell line (lung carcinoma) (1997) (16)
Inhibition of adhesion molecules by budesonide on a human epithelial cell line (lung carcinoma) (1997) (16)
Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience. (2018) (16)
Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study (2018) (16)
Spices to Control COVID-19 Symptoms: Yes, but Not Only… (2020) (16)
Single-Dose Oral Tolerance Test with Alternative Compounds for the Management of Adverse Reactions to Drugs (2002) (16)
Sublingual immunotherapy: where do we stand? Present and future. (2009) (16)
Catching allergy by a simple questionnaire (2015) (16)
Assessing biomarkers in a real-world severe asthma study (ARIETTA). (2016) (16)
Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP. (2021) (16)
The Effect of Aging on Host Defences (1991) (15)
Update on immunotherapy for the treatment of asthma (2016) (15)
α1-Acid glycoprotein (α1-AGP) on the membrane of human lymphocytes: possible involvement in cellular activation (1987) (15)
Adherence to treatment in allergic respiratory diseases (2018) (15)
The Clinical Efficacy of a Sublingual Monomeric Allergoid at Different Maintenance Doses: A Randomized Controlled Trial (2010) (15)
New insights in allergen avoidance measures for mite and pet sensitized patients. A critical appraisal. (2005) (15)
Functional involvement of the LFA-1/ICAM-1 adhesion system in the autologous mixed lymphocyte reaction. (1990) (15)
Randomized controlled trial of desloratadine for persistent allergic rhinitis: correlations between symptom improvement and quality of life. (2013) (15)
Alternative routes for allergen-specific immunotherapy. (1996) (15)
Allergen-specific immunotherapy in asthmatic children: from the basis to clinical applications (2013) (15)
Barriers to Asthma Treatment in the United States: Results From the Global Asthma Physician and Patient Survey (2009) (15)
SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis. (2016) (15)
Eligibility for treatment with omalizumab in Italy and Germany. (2014) (15)
Aerobiologic particle sampling by a new personal collector (Partrap FA52) in comparison to the Hirst (Burkard) sampler (1997) (15)
Prevalence of allergy to Cypress (2002) (14)
Sublingual and oral immunotherapy. (2004) (14)
Functional study of T lymphocyte responsiveness in patients with dementia of the Alzheimer type (1989) (14)
Sublingual IT in OAS (2000) (14)
Effects of Triamcinolone Acetonide on Adult Human Lung Fibroblasts: Decrease in Proliferation, Surface Molecule Expression and Mediator Release (2002) (14)
Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment (2019) (14)
Inhibition of T3 Mediated T‐Cell Proliferation by Ca2+‐Channel Blockers and Inhibitors of Ca2+/Phospholipid‐Dependent Kinase (1986) (14)
Potential benefit of omalizumab in respiratory diseases. (2014) (14)
Sublingual immunotherapy: focus on tablets. (2015) (14)
Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice. (2018) (14)
Advances in allergen-specific immunotherapy. (2009) (14)
Severe skin reaction due to excipients of an oral iron treatment (2007) (14)
SIT: efficacy depends on product, not on route of application (2012) (14)
Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID‐ERD: Results from two randomized placebo‐controlled phase 3 trials (2021) (14)
Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life. (2019) (14)
One Hundred Ten Years of Allergen Immunotherapy: A Broad Look Into the Future. (2021) (14)
Characterization of circadian COPD symptoms by phenotype: Methodology of the STORICO observational study. (2017) (13)
Human lung myofibroblasts as effectors of the inflammatory process: the common receptor gamma chain is induced by Th2 cytokines, and CD40 ligand is induced by lipopolysaccharide, thrombin and TNF-alpha. (2002) (13)
Using the congestion quantifier seven-item test to assess change in patient symptoms and their impact. (2008) (13)
Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases. (2016) (13)
Non-injection routes for allergen immunotherapy: focus on sublingual immunotherapy. (2006) (13)
Importance of fibroblasts-myofibroblasts in asthma-induced airway remodeling. (2007) (13)
Treatable traits in chronic rhinosinusitis with nasal polyps. (2019) (13)
Managing Allergic Rhinitis in the Pharmacy: An ARIA Guide for Implementation in Practice (2020) (13)
Immunotherapy in polysensitized patients: new chances for the allergists? (2012) (13)
Severe asthma: Entering an era of new concepts and emerging therapies: Highlights of the 4th international severe asthma forum, Madrid, 2018 (2019) (13)
Allergic rhinitis and asthma ad hoc survey: clinical and psychological perspectives (2007) (13)
Treatment of allergic diseases during pregnancy. (1997) (13)
Low concentrations of cytokines produced by allergen‐stimulated peripheral blood mononuclear cells have potent effects on nasal polyp‐derived fibroblasts (2003) (13)
Influence of H1‐receptor antagonists on adhesion molecules and cellular traffic (1995) (13)
Local nasal immunotherapy: experimental evidences and general considerations (1997) (13)
A new tool for inhalers’ use and adherence monitoring: the Amiko® validation trial (2016) (13)
Clinical and therapeutic aspects of allergic asthma in adolescents. (2003) (12)
The role of the pharmacy in the management of bronchial asthma: A literature-based evaluation. (2017) (12)
Activation of T lymphocytes and autologous mixed lymphocyte reaction in allergic patients. (1984) (12)
Persistent Allergic Rhinitis and the XPERT Study (2011) (12)
Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets (2022) (12)
Effective long-term alpha-interferon treatment for hypereosinophilic syndrome. (1995) (12)
Prevalence of perennial severe allergic asthma in Italy and effectiveness of omalizumab in its management: PROXIMA – an observational, 2 phase, patient reported outcomes study (2015) (12)
The relationship between asthma control and quality-of-life impairment due to chronic cough: a real-life study. (2008) (12)
Rhinitis: adherence to treatment and new technologies (2017) (12)
Extrafine triple therapy in patients with asthma and persistent airflow limitation (2020) (12)
Comparison of the colony-forming capacities of human T-lymphocyte subpopulations. (1981) (12)
New drugs in early-stage clinical trials for allergic rhinitis (2019) (12)
A review of the use of fluticasone furoate since its launch (2011) (12)
Bilateral Gasser's ganglion sarcoidosis: diagnosis, treatment and unsolved questions. (2005) (12)
Clinical characteristics associated with conjunctival inflammation in allergic rhinoconjunctivitis. (2015) (12)
Molecular diagnosis and the Italian Board for ISAC. (2014) (12)
Patient-reported outcomes in asthma clinical trials (2018) (12)
Eosinophils, specific hyperreactivity and occurrence of late phase reaction in allergic rhinitis. (2005) (12)
Clinical presentation at the onset of COVID-19 and allergic rhinoconjunctivitis (2020) (12)
Prospective, single-arm, longitudinal study of biomarkers in real-world patients with severe asthma. (2020) (12)
Sublingual immunotherapy for allergic respiratory diseases: efficacy and safety. (2011) (12)
The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life (2019) (12)
100 Years of Immunotherapy: The Monaco Charter (2012) (12)
How do T cells mediate autoimmune thyroiditis? (1986) (11)
Antiallergic activity of topical lodoxamide on in vivo and in vitro models (1996) (11)
Drug Treatment of Allergic Conjunctivitis (1992) (11)
Disability in Moderate Chronic Obstructive Pulmonary Disease: Prevalence, Burden and Assessment - Results from a Real-Life Study (2015) (11)
Cetirizine does not influence the immune response. (1992) (11)
What we should learn from the London Olympics. (2013) (11)
Coordinated IgG2 and IgE responses as a marker of allergen immunotherapy efficacy (2021) (11)
The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: The results of a double blind, placebo controlled, multicenter clinical trial (2014) (11)
Effects of allergen immunotherapy in the MASK‐air study: a proof‐of‐concept analysis (2021) (11)
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments (2021) (11)
Quality of life in respiratory allergy. (2001) (11)
Effectiveness of pulmonary rehabilitation in severe asthma: a retrospective data analysis (2020) (11)
Knowledge and health care resource allocation: CME/CPD course guidelines-based efficacy. (2012) (11)
Deficiency of the autologous mixed lymphocyte reaction in patients with autoimmune thyroid disease. (1984) (11)
Management of anaphylaxis due to COVID‐19 vaccines in the elderly (2021) (11)
The path to personalized medicine in asthma (2016) (11)
New perspectives in the treatment of allergic rhinitis and asthma in children (2007) (11)
Montelukast effects on inflammation in allergic rhinitis: a double blind placebo controlled pilot study. (2012) (11)
Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis (2020) (11)
Evidence of T-lymphocyte functional impairment in Huntington's disease. (1986) (11)
Cetirizine reduces conjunctival nonspecific hyperreactivity in children with mite allergy. (1998) (11)
Effect of an educational intervention delivered by pharmacists on adherence to treatment, disease control and lung function in patients with asthma. (2020) (11)
Incidence of digestive diseases in patients with adverse reactions to foods. (1988) (11)
Minimal important difference of the Chronic Urticaria Quality of Life Questionnaire (CU‐Q2oL) (2019) (11)
Melkersson–Rosenthal syndrome associated with parvovirus b19 viraemia and haemophagocytic lymphohistiocytosis (2009) (11)
Biomarkers in obstructive respiratory diseases: an update. (2012) (11)
Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma (2016) (11)
Severe asthma: One disease and multiple definitions (2021) (11)
Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (2020) (10)
The prevalence of sleep impairments and predictors of sleep quality among patients with asthma (2020) (10)
Effect of statins on fibroblasts from human nasal polyps and turbinates. (2008) (10)
The perception of allergen-specific immunotherapy among Italian general practitioners. (2014) (10)
Disease-modifying anti-asthmatic drugs (2022) (10)
Coping with asthma: is the physician able to identify patient's behaviour? (2012) (10)
Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER (2020) (10)
Measurement of nasal IgE in an epidemiological study: assessment of its diagnostic value in respiratory allergy. (2004) (10)
Suppressor Activity of T Cells Bearing Fc Receptors for IgG on Lymphoid Colony Formation (1980) (10)
Does normal lymphocyte DNA synthesis in response to PHA exclude cell-mediated immunodepression? (1986) (10)
Allergen immunotherapy as add-on to biologic agents (2018) (10)
Eosinophilic esophagitis: which role for food and inhalant allergens? (2012) (10)
Anti-interleukin-5 (mepolizumab) therapy for a hypereosinophilic syndrome (2007) (10)
ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study (2022) (10)
ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy (2021) (10)
Effectiveness and safety of mepolizumab in real-world clinical practice: The REALITI-A study (2019) (10)
Expression of very late activation antigen-1 on intrathyroid lymphocytes in autoimmune thyroid disease (1992) (10)
Aerobiological diagnosis of respiratory allergy by a personal sampler: two case reports. (2003) (10)
Antihistamines in the treatment of bronchial asthma. Present knowledge and future perspectives. (2001) (10)
The era of research collaborations: new models for working together (2017) (10)
Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. (2022) (10)
Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study (2019) (10)
Oral cromolyn in food allergy: in vivo and in vitro effects. (1986) (10)
Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (2020) (10)
Sublingual immunotherapy for allergic rhinitis: an update (2011) (10)
Preliminary Evidence for ‘Aberrant’ Expression of the Leukocyte Integrin LFA-1 (CD11a/CD18) on Conjunctival Epithelial Cells of Patients with Mite Allergy (2001) (10)
Sublingual immunotherapy: no more doubts. (2005) (10)
Impact of children's respiratory allergies on caregivers. (2005) (9)
Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases-Meeting Report (Part 2). (2019) (9)
Clinical Practice of Allergen Immunotherapy for Allergic Rhinoconjunctivitis and Asthma: An Expert Panel Report. (2020) (9)
Public awareness on cystic fibrosis: results from a national pragmatic survey (2015) (9)
Fall episodes in elderly patients with asthma and COPD – A pilot study (2018) (9)
Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate. (2014) (9)
Topical acetylsalicylic acid in the treatment of allergic pollinosic conjunctivitis. (1992) (9)
The relationship between clinical efficacy of specific immunotherapy and serum intercellular adhesion molecule-1 levels. (1998) (9)
The effect of methimazole on the immune system is unlikely to operate directly on T lymphocytes (1990) (9)
Biosimilars in allergic diseases (2016) (9)
Allergen immunotherapy in asthma; what is new? (2015) (9)
Effect of grass sublingual tablet immunotherapy is similar in children and adults: A Bayesian approach to design pediatric sublingual immunotherapy trials (2017) (9)
Chronic Obstructive Pulmonary Disease Patient Well-Being and Its Relationship with Clinical and Patient-Reported Outcomes: A Real-Life Observational Study (2011) (9)
Inhibiton of the colony-forming capacity of human T-lymphocytes exerted by theophylline. (1988) (9)
Molecular allergy diagnosis: we need to become more knowledgeable. (2012) (9)
Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases-Meeting Report (Part 1). (2019) (9)
Biologics and airway remodeling in severe asthma (2022) (9)
Effects of an adjunctive treatment with Bacillus subtilis for food allergy. (1986) (9)
Anomalous asthma and chronic obstructive pulmonary disease Google Trends patterns during the COVID-19 pandemic (2020) (9)
The safety of monoclonal antibodies in asthma (2016) (9)
Safety of allergen-specific sublingual immunotherapy and nasal immunotherapy. (2003) (9)
Continuing Medical Education: an international reality (2005) (8)
Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens (2022) (8)
Comparative effects of terfenadine and loratadine in the treatment of hay fever. (1991) (8)
Safety of celecoxib in patients with adverse reactions to nimesulide (2005) (8)
Levocetirizine in persistent allergic rhinitis: continuous or on-demand use? A pilot study. (2008) (8)
The COPD multi-dimensional phenotype: A new classification from the STORICO Italian observational study (2019) (8)
Effects of Mizolastine in vitro on Human Immunocompetent and Airway Cells: Evidence for Safety and Additional Property (2000) (8)
Allergic rhinitis in the Italian population evaluated through the national database of general practitioners (2007) (8)
Psychometric properties of the portuguese version of the chronic urticaria quality of life questionnaire (CU-Q2oL) (2019) (8)
Asthma management in a specialist setting: Results of an Italian Respiratory Society survey. (2017) (8)
Allergens and bacteria interaction in the induction of basophil activation: is this the lost ring between allergy and infections in pediatric patients? (2012) (8)
Escaping the trap of allergic rhinitis (2015) (8)
The WEB-based Asthma Control: an intriguing connection or a dangerous hazard? (2015) (8)
A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis. (2015) (8)
New aspects of glucocorticoid therapy in immunological disorders: Focus on deflazacort: Discussion (1993) (8)
Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study (2020) (8)
COPD treatment: real life and experimental effects on peripheral NK cells, their receptors expression and their IFN-γ secretion. (2012) (8)
Non‐steroidal treatment of pollen‐induced conjunctivitis: comparison of different pharmacological protocols (1991) (8)
Pharmacologic treatment of adverse reactions to foods: comparison of different protocols. (1987) (8)
Abnormalities of circulating T cell subsets in atopy: influence of specific immunotherapy. (1983) (8)
Inhibition of autologous mixed lymphocyte reaction by aggregated IgG molecules (1982) (8)
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life☆ (2021) (8)
Allergen‐specific conjunctival challenge in children with allergic asthma: a clinical tool (1994) (8)
Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases. (2022) (8)
Gastroesophageal reflux and asthma: when, how, and why (2020) (8)
Azelastine eye drops reduce conjunctival hyperresponsiveness to hyperosmolar glucose challenge in children with asymptomatic mite conjunctivitis. (1999) (8)
Long-term efficacy of injected allergen immunotherapy for treatment of grass pollen allergy in elderly patients with allergic rhinitis. (2020) (8)
Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets (2022) (8)
Biologics and global burden of asthma: A worldwide portrait and a call for action (2021) (8)
Efficacy against asthma demonstrated for a house dust mite allergen immunotherapy tablet (2009) (7)
Allergen immunotherapy: the growing role of observational and randomised trial “real-world evidence” (2021) (7)
Intraepithelial γ/δ-Positive T Lymphocytes and Intestinal Villous Atrophy (1996) (7)
Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GA 2 LEN platform. The (2009) (7)
Topical anti-inflammatory drugs in the treatment of allergic pollinosic conjunctivitis: a comparative double-blind study. (1992) (7)
Omalizumab for Idiopathic Nonhistaminergic Angioedema: Evidence for Efficacy in 2 Patients (2018) (7)
Diagnosis and treatment of hereditary angioedema. (2012) (7)
Wellbeing, Illness Perception and Coping Strategies in Italian Celiac Patients (2012) (7)
Novel in silico technology in combination with microarrays: a state-of-the-art technology for allergy diagnosis and management? (2014) (7)
Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis (2020) (7)
The management of asthma in the phenotype and biomarker era: The proposal of a new diagnostic-therapeutic model (2016) (7)
Plasma Galectin-3 and urine proteomics predict FEV1 improvement in omalizumab-treated patients with severe allergic asthma: Results from the PROXIMA sub-study☆ (2020) (7)
Allergen-driven HLA-G expression and secretion in peripheral blood mononuclear cells from allergic rhinitis patients. (2016) (7)
Will Sublingual Immunotherapy Offer Benefit for Asthma? (2013) (7)
Serum cytotoxic T lymphocyte-associated antigen 4 in Hymenoptera venom allergy and its modulation by specific immunotherapy. (2009) (7)
Allergic rhinitis in asthma. (2011) (7)
Responders and nonresponders to pharmacotherapy and allergen immunotherapy (2019) (7)
Euro coins and contact dermatitis (2004) (7)
Umeclidinium for the treatment of uncontrolled asthma (2017) (7)
Reply to the Letter by Dr Fleming Madsen (EAACI ‘Standards for practical allergen‐specific immunotherapy’) (2008) (7)
Is alternative medicine acceptable in allergology? (2000) (7)
Fluticasone propionate/formoterol: a fixed-combination therapy with flexible dosage. (2014) (7)
A Real-World Evaluation of Clinical Outcomes of Biologicals and Bronchial Thermoplasty for Severe Refractory Asthma (BIOTERM) (2021) (6)
Protective effects of deflazacort on allergen-specific conjunctival challenge (2005) (6)
The Scope of Pharmacological and Clinical Effects of Modern Antihistamines, With a Special Focus on Rupatadine: Proceedings from a Satellite Symposium held at the 21st World Allergy Congress, Buenos Aires, December 8, 2009 (2010) (6)
Cetirizine-induced downregulation of airway fibroblast proliferation and function: a rationale for a different approach to allergy treatment? (2000) (6)
[ARIA 2016 executive summary: integrated care pathways for predictive medicine across the life cycle]. (2017) (6)
Investigational drugs for allergic rhinitis (2010) (6)
Foreword. Evaluation and management of patients with asthma and allergic rhinitis: exploring the potential role for leukotriene receptor antagonists (2003) (6)
Clinically relevant effect of rupatadine 20 mg and 10 mg in seasonal allergic rhinitis: a pooled responder analysis (2019) (6)
Ranking in importance of allergen extract characteristics for sublingual immunotherapy by Italian specialists. (2014) (6)
The Portuguese version of Rhinitis and Asthma Patient's Perspective (RAPP): Validation and assessment. (2020) (6)
Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma (2021) (6)
Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients? (2017) (6)
Allergen immunotherapy for respiratory allergy: Quality appraisal of observational comparative effectiveness studies using the REal Life Evidence AssessmeNt Tool. An EAACI methodology committee analysis (2021) (6)
Real-life survey on severe asthma patients during COVID-19 lockdown in Italy (2021) (6)
Functional characterization of a regulatory human T-cell subpopulation increasing during autologous MLR. (1986) (6)
DRACMA one year after: Which changes have occurred in diagnosis and treatment of CMA in Italy? (2011) (6)
[ARIA 2016 executive summary: Integrated care pathways for predictive medicine throughout the life cycle in Argentina]. (2017) (6)
Immune Response to Mycobacteria (1988) (6)
Formoterol by pressurized metered-dose aerosol or dry powder on airway obstruction and lung hyperinflation in partially reversible COPD. (2011) (6)
Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms (2020) (6)
Additional file 5: of World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Vitamin D (2016) (6)
Expert Review of Clinical Immunology : a breakthrough in the future (2005) (6)
Terfenadine in allergic chronic cough in children (1992) (6)
Clinical features associated with a doctor-diagnosis of bronchiectasis in the Severe Asthma Network in Italy (SANI) registry (2020) (6)
Ketotifen treatment of adverse reactions to foods: clinical and immunological effects. (1986) (6)
Autologous mixed lymphocyte reaction in Graves' disease: relationship to clinical status. (1985) (6)
Evaluation of asthma control in the pharmacy: an Italian cross-sectional study. (2017) (6)
Minimal Persistent Inflammation in Allergic Rhinitis (2006) (6)
The functional connection between oral allergy syndrome and united airways disease assessed by oral challenge. (2012) (6)
Association Between a Type 2 Inflammatory Disease Burden Score and Outcomes Among Patients with Asthma (2021) (6)
The Scope of Pharmacological and Clinical Effects of Modern Antihistamines, With a Special Focus on Rupatadine (2010) (6)
Rupatadine for the treatment of allergic rhinitis and urticaria: a look at the clinical data (2014) (6)
Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review (2021) (6)
New insights in sublingual immunotherapy (2006) (6)
Implementation of the MASK-Air® App for Rhinitis and Asthma in Older Adults: MASK@Puglia Pilot Study (2021) (6)
Personalized medicine and allergen immunotherapy: the beginning of a new era? (2021) (6)
Towards the Grade of Recommendations, Assessment, Development and Evaluation system: methods and results of budesonide/formoterol maintenance and reliever therapy research. (2011) (6)
The perception of Obstructive Sleep Apnoea/Hypopnoea Syndrome (OSAHS) among Italian general practitioners (2015) (6)
Management of Allergic Conjunctivitis (1996) (6)
A 3-Year Randomized Controlled Study with Sublingual Immunotherapy in Mite-Induced Respiratory Allergy (2005) (6)
Alterations in helper-specific circulating T lymphocytes and in the autologous mixed lymphocyte reaction in chronic hepatitis B. (1987) (6)
Molecular Events in Allergic Inflammation: Expression of adhesion molecules and their modulation (1998) (6)
Review of Desloratadine Data Using the ARIA Guidelines (2012) (6)
Cytoprotective drugs: a new perspective in the treatment of adverse reactions to foods. (1988) (6)
Intraepithelial gamma/delta-positive T lymphocytes and intestinal villous atrophy. (1996) (5)
Erratum to "IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper" [World Allergy Organ J 13/2 (2020) 100080]. (2021) (5)
Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center (2022) (5)
Asthma: developments in targeted therapy (2012) (5)
T cell-mediated mechanisms in autoimmune thyroiditis (1986) (5)
ARIA masterclass 2018: From guidelines to real-life implementation. (2019) (5)
The Possible Role Of Climate Changes In Variations Of Pollen Seasons And Allergic Sensitizations Over 27 Years (2010) (5)
EUFOREA treatment algorithm for allergic rhinitis. (2020) (5)
Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies (2021) (5)
WAO-ARIA consensus on chronic cough - Part II: Phenotypes and mechanisms of abnormal cough presentation — Updates inCOVID-19 (2021) (5)
Topical azelastine reduces eosinophil activation and ICAM-1 expression on nasal epithelial cells: an antiallergic activity. (1996) (5)
Exacerbation Reduction and Early and Sustained Improvements in SGRQ, Lung Function, and Symptoms of Nasal Polyposis with Benralizumab for Severe, Eosinophilic Asthma: Phase IIIb ANDHI Trial (2020) (5)
Comparison of the immunomodulation of prednisone, dexamethasone and deflazacort on T-cell activation pathways and gamma-interferon production (1989) (5)
Why a registry of Chronic Urticaria (CUR) is needed (2017) (5)
Clinical and therapeutic aspects of allergic asthma in adolescents (2003) (5)
Evolving phenotypes to endotypes: is precision medicine achievable in asthma? (2020) (5)
The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians (2020) (5)
Considerations about the evaluation of the SLIT meta-analyses. (2010) (5)
Grass pollen and asthma (1992) (5)
''United Airways Disease'' and Phenotypic Peculiarities of Respiratory Allergy in Immigrants (2009) (5)
Local nasal immunotherapy for allergic rhinitis: A systematic review and meta‐analysis (2022) (5)
Safety Profile of Sublingual Immunotherapy (2006) (5)
COVID‐19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations (2022) (5)
Oral and sublingual immunotherapy: general aspects and critical considerations. (1999) (5)
Allergic Rhinitis and its Impact on Asthma (ARIA) 2010 Revision Full Online version - published in the Journal of Allergy and Clinical Immunology (2010) (5)
New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine (2022) (5)
Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry (2020) (5)
Serum intercellular adhesion molecule-1 and long-term response to IFN-alpha2b therapy in chronic hepatitis C. (1998) (5)
Salbutamol: How Does it Enter Smooth Muscle Cells? (2012) (5)
Asthma – Rhinitis Comorbidity (2003) (5)
Benralizumab for the treatment of asthma. (2017) (5)
Nasal Polyposis Quality of Life (NPQ): Development and Validation of the First Specific Quality of Life Questionnaire for Chronic Rhinosinusitis with Nasal Polyps (2022) (5)
Infiltrating γ/gd T-cell receptor-positive lymphocytes in Hashimoto’s thyroiditis, Graves’ disease and papillary thyroid cancer (1995) (5)
New treatment options in allergic rhinitis: patient considerations and the role of ciclesonide (2008) (5)
A critical appraisal on AIT in childhood asthma (2018) (5)
Biologics in severe asthma: the role of real-world evidence from registries (2022) (5)
Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK‐air® real‐world data (2022) (5)
Latin American chronic urticaria registry (CUR) contribution to the understanding and knowledge of the disease in the region (2019) (5)
Personalized Management of Patients with Chronic Rhinosinusitis with Nasal Polyps in Clinical Practice: A Multidisciplinary Consensus Statement (2022) (5)
Evaluation of food‐pollen cross‐reactivity by nose–mouth cross‐challenge in pollinosis with oral allergy syndrome (2005) (5)
The Scope of Pharmacological and Clinical Effects of Modern Antihistamines, With a Special Focus on Rupatadine: Proceedings from a Satellite Symposium held at the 21st World Allergy Congress, Buenos Aires, December 8, 2009 (2010) (5)
ARIA update 2008: allergic rhinitis and its effect on asthma (2009) (5)
Clinically significant differences in patient-reported outcomes evaluations in chronic spontaneous urticaria. (2020) (5)
A Role for Pathogenesis-Related Proteins in Poly-Sensitized Allergic Patients with Eosinophilic Esophagitis: Clinical and Endoscopic Features (2014) (5)
Infiltrating gamma/delta T-cell receptor-positive lymphocytes in Hashimoto's thyroiditis, Graves' disease and papillary thyroid cancer. (1995) (5)
Nasal polyps impact in severe asthma patients: evidences from the SANI (2020) (5)
T cell activation surface markers and autologous mixed lymphocyte reaction do not differ in true and pseudo food allergy. (1987) (4)
Prospective Italian real‐world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports (2021) (4)
[GA(2)LEN (Global Allergy and Asthma European Network): European network of excellence for asthma and allergic diseases]. (2009) (4)
Choose your outcomes: From the mean to the personalized assessment of outcomes in COPD. An exploratory pragmatic survey. (2016) (4)
Adhesion molecules in allergy. (1996) (4)
Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5) (2017) (4)
Quality of life in patients with adverse reactions to drugs: Preliminary results from a new questionnaire (2004) (4)
Immunologic and clinical evaluation of a 12-month course of specific immunotherapy. (1989) (4)
Do the current guidelines for asthma pharmacotherapy encourage over-treatment? (2020) (4)
Asthma phenotyping in primary care: applying the International Severe Asthma Registry eosinophil phenotype algorithm across all asthma severities. (2021) (4)
Characterization of Eosinophilic and Non-Eosinophilic Severe Asthma Phenotypes and Proportion of Patients with These Phenotypes in the International Severe Asthma Registry (ISAR) (2020) (4)
The asthma-rhinitis association: Between the clinical hypothesis and the scientific theory (2003) (4)
Choosing wisely in Allergology: a Slow Medicine approach to the discipline promoted by the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC) (2015) (4)
Density Distribution Profiles of T Cells: TM, TG and TA Cells and Response Patterns in Autologous Versus Allogeneic MLRs (1982) (4)
Long-Term Treatment of Persistent Allergic Rhinitis with Levocetirizine (2007) (4)
Angioedema after administration of methylprednisolone to treat drug allergy: a case report (2007) (4)
Is Health-Related Quality of Life Associated with Upper and Lower Airway Inflammation in Asthmatics? (2013) (4)
The inflammatory network. (2002) (4)
Nonsteroidal Antiallergic Treatments in Allergic Rhinitis (2000) (4)
Emerging sublingual immunotherapy drugs (2010) (4)
Allergen immunotherapy against house dust mites in patients with local allergic rhinitis and asthma (2021) (4)
Oxatomide does not influence immune response: further support for its use in allergic disorders (1987) (4)
Allergen-specific conjunctival challenge in asthma. An additional diagnostic tool to define sensitization. (1997) (4)
Allergen immunotherapy in MASK‐air users in real‐life: Results of a Bayesian mixed‐effects model (2022) (4)
Effectiveness of vacuum-cleaning in removing Fel d 1 allergen from cotton fabrics exposed to cats. (2007) (4)
Beliefs and preferences regarding biological treatments for severe asthma (2020) (4)
Personalizing the approach to asthma treatment (2018) (4)
The perception of allergen-specific immunotherapy among chest physicians: an Italian survey. (2014) (4)
What do we need to learn to optimize the SLIT alternative? (2006) (4)
[Immunotherapy in Latin America. From the past to the future]. (2008) (4)
Alpha 1-acid glycoprotein (alpha 1-AGP) on the membrane of human lymphocytes: possible involvement in cellular activation. (1987) (4)
What drives inhaler prescription for asthma patients? Results from a real-life retrospective analysis. (2020) (4)
Will precision medicine be available for all patients in the near future? (2019) (4)
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis (2022) (4)
Consensus on allergen specific immunotherapy. (2013) (4)
Allergic rhinitis and quality of life: Where are we? (2003) (4)
What we know and still ignore on COVID‐19 immune pathogenesis and a proposal based on the experience of allergic disorders (2021) (4)
Drugs and the immune response: knowledge and perspectives in allergology. (1989) (4)
Pollen mixtures used as health food may be a harmful source of allergens. (2000) (4)
A model of allergen-driven human airway contraction: beta2 pathway dysfunction without cytokine involvement. (2005) (4)
Poster 1002: Galectin-3 as predictive biomarker of airways remodeling modulation in omalizumab treated severe asthma patients (2014) (4)
Eosinophilic and Noneosinophilic Asthma (2021) (4)
Adhesion molecules and H1‐antihistamines (1997) (3)
WAO-ARIA consensus on chronic cough – Part 1: Role of TRP channels in neurogenic inflammation of cough neuronal pathways (2021) (3)
Long-term effects of allergen sublingual immunotherapy (2019) (3)
ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines -- an EAACI-ARIA Position Paper (2020) (3)
Personalized Approach to Severe Asthma (2018) (3)
Different aspects of severe asthma in real life: Role of Staphylococcus aureus enterotoxins and correlation to comorbidities and disease severity (2022) (3)
REALITI-A study: Real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma. (2022) (3)
[Anti-leukotriene agents: rationale for and prospects of use]. (1996) (3)
Reply to correspondence to ‘Differentiation of COVID‐19 signs and symptoms from allergic rhinitis and common cold: An ARIA‐EAACI‐GA2LEN consensus’ (2022) (3)
ABS008: Asthma management and the PCP: Findings of the global asthma physician and patient (GAPP) survey (2006) (3)
Direct and prolonged exposure to dogs does not influence the degree of skin prick test positivity to dog allergen. (2005) (3)
Methimazole, γ-”Interferon and Graves′ Disease (1987) (3)
Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID‐19? (2021) (3)
Anti-IgE and airway remodelling: Omalizumab affects reticular basement membrane thickness in severe persistent atopic asthma (2011) (3)
A new allergic rhinitis therapy (MP29-02) is more effective than current first line monotherapies in providing allergic rhinitis patients relief from their nasal and ocular symptoms (rTNSS, rT5SS, rT7SS) (2013) (3)
Evaluation of the effects of zafirlukast 40 mg b.i.d. in addition to preexisting therapy of high-dose inhaled steroids on symptomatic patients with reversible respiratory obstruction: preliminary data. (2000) (3)
Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care (2020) (3)
Omalizumab, an Anti-IgE Antibody, Provides Parallel Improvements in Symptoms of Allergic Asthma and Perennial Allergic Rhinitis in Patients With Both Diseases: The SOLAR Stud (2003) (3)
Relationship between degree of nonspecific hyperresponsiveness and number of positive skin tests in asthmatics. (2000) (3)
Academic productivity of young people with allergic rhinitis: A MASK-air® study. (2022) (3)
Long-lasting effect according to the duration of sublingual immunotherapy: a 15-year prospective study (2007) (3)
Rhinitis and asthma patient perspective (RAPP): clinical utility and predictive value. (2021) (3)
Comparison of rhinitis treatments using MASK‐air® data and considering the minimal important difference (2022) (3)
Dupilumab Improves Upper and Lower Airway Outcome Measures in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma: Pooled Results from the SINUS-24 and SINUS-52 Phase 3 Studies (2019) (3)
Antiproliferative and anti remodelling effect of beclomethasone dipropionate, formoterol and salbutamol alone or in combination in primary human bronchial fibroblasts (2007) (3)
P171 Can the turbu+™ adherence programme contribute to improved adherence to asthma controller treatment in italy? (2018) (3)
Connected real-life research, a pillar of P4 medicine (2020) (3)
Serum Ctla-4 In Hymenoptera Venom Allergy And Its Modulation By Specific Immunotherapy (2009) (3)
The effect of the COVID-19 pandemic on severe asthma care in Europe: will care change for good? (2022) (3)
Digital Coaching Using Smart Inhaler Technology to Improve Asthma Management in Patients With Asthma in Italy: Community-Based Study (2022) (3)
Year in review: allergen immunotherapy. (2015) (3)
Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app. (2022) (3)
In Subjects with Persistent Allergic Rhinitis (PER) Treated with Desloratadine, Improvements in Total 5-Symptom Scores (T5SS) and Rhinoconjunctivitis Quality of Life Questionnaire-Standardized (RQLQ-S) Correlate with Disease Burden as Measured using a Simple Visual Analog Scale (VAS) (2009) (3)
Asthma controller therapy: role of antileukotrienes, a new therapeutic class. (1999) (3)
The management of paediatric allergy: not everybody's cup of tea – 10–11th February 2012 (2013) (3)
Reducing the Rate of Severe Asthma Exacerbations Using Single-Inhaler Extrafine BDP/FF/GB Combination Compared to BDP/FF in Patients with Uncontrolled Asthma: Pooled Results from the TRIMARAN and TRIGGER Studies (2019) (3)
Overcoming Barriers to the Effective Management of Severe Asthma in Italy (2021) (3)
EAACI Research and Outreach Committee: Improving standards and facilitating global collaboration through a Research Excellence Network (2020) (3)
Extended nitric oxide analysis in patients with chronic rhinosinusitis with nasal polyps, with or without associated asthma (2020) (3)
VCAM‐1 in conjunctival inflammation (2002) (3)
EUFOREA Rhinology Research Forum 2017: report of the brainstorming sessions on endotype-driven treatment, patient empowerment and digital future in airways care (2018) (3)
Outcomes of Non-Mucosa Sparing Endoscopic Sinus Surgery (Partial Reboot) in Refractory Chronic Rhinosinusitis with Nasal Polyposis: An Academic Hospital Experience. (2022) (3)
Immunoactive preparations and regulatory responses in the respiratory tract: potential for clinical application in chronic inflammatory airway diseases (2020) (3)
Will Sublingual Immunotherapy Become an Approved Treatment Method in the United States? (2011) (3)
Preseasonal specific immunotherapy with modified Phleum pratense allergenic extracts: tolerability and effects. (1997) (3)
A multi-allergen ELISA screening method. Comparison with Pharmacia CAP system and Phazet skin prick test. (1992) (3)
Allergen-Specific Sublingual Immunotherapy for Respiratory Allergy (2012) (3)
Factors influencing the prescription of allergen immunotherapy: the allergen immunotherapy decision analysis (AIDA) study. (2013) (2)
The challenges of chronic urticaria part 2: Pharmacological treatment, chronic inducible urticaria, urticaria in special situations☆ (2021) (2)
Antihistamines in atopic dermatitis (1989) (2)
Critical evaluation of asthma biomarkers in clinical practice (2022) (2)
60Co therapy as an "allergic breakthrough" in a case of food allergy. (1984) (2)
The cross-cultural validation of the English version of RhinAsthma patient’s perspective (RAPP) (2020) (2)
Successful treatment of churg-strauss syndrome with mycophenolate mofetil (2003) (2)
The perception of allergen-specific immunotherapy among Italian general practitioners. (2012) (2)
Erratum to: Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA (2016) (2)
Comparison of Direct Healthcare Costs Associated with Chronic Spontaneous /Idiopathic Urticaria in 7 Countries - Results from the Assure-CSU Study (2016) (2)
Inflammation: Rhinitis and asthma (1997) (2)
Fenoterol effects on the in vitro immune response. (1988) (2)
Clinical efficacy of sublingual immunotherapy tablets for allergic rhinitis is unlikely to be derived from in vitro allergen-release data (2019) (2)
Impact of Urticaria: QOL and Performance (2010) (2)
In vitro immune response to two new antihistamines (astemizole and levocabastine) (1988) (2)
Allergen immunotherapy: clinical and practical education of Italian trainees in allergy and clinical immunology schools. (2013) (2)
200 Nasal immunotherapy (NIT) to parietaria: Follow-up of a double blind study (1996) (2)
Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride (2022) (2)
[ARIA (Allergic Rhinitis and its Impact on Asthma). Achievements in 10 years and future needs in Latin America]. (2013) (2)
Severe asthma and personalized approach in the choice of biologic (2022) (2)
Appropriateness in allergic respiratory diseases health care in Italy: definitions and organizational aspects (2016) (2)
Introduction. Expanding the anti-allergy therapeutic horizon. (2002) (2)
History of the World Allergy Organization: Innovation in Continuity 2008–2009 (2011) (2)
Sublingual Immunotherapy With Honeybee Venom Is Effective In Patients With Large Local Reactions Due To Bee Sting. A Randomised, Double Blind Placebo Controlled Trial (2008) (2)
Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life (2022) (2)
T lymphocyte subsets implicated in cytotoxicity in autologous hepatocytes in chronic active hepatitis patients with active viral replication. (1986) (2)
Mild/Moderate Asthma Network in Italy (MANI): a long-term observational study (2021) (2)
A new AR therapy (MP29-02*): all of ARIA in one puff (2015) (2)
Circulating T cell subsets in euthyroid Graves’ disease (1983) (2)
Long-acting anti-muscarinic agents (LAMA) frequency of use and clinical features of patients with severe asthma in real-life setting: data from the Severe Asthma Network in Italy (SANI) registry (2019) (2)
Microarray Immunodiagnostics for Aeroallergens (2019) (2)
Prolonged effect of allergen sublingual immunotherapy to grass pollen (2018) (2)
Characteristics of prominent response to triple therapy in patients with asthma uncontrolled on ICS/LABA: A stratified analysis of the TRIMARAN and TRIGGER studies (2019) (2)
Immunoregulatory T Cell Subpopulations in Man (1980) (2)
Reply [to letters from Dr. Chipps and Dr. Spector] (2011) (2)
Physicians’ prescribing behaviour and clinical practice patterns for allergic rhinitis management in Italy (2020) (2)
Antihistamines: back to the future. Summary of the conclusions. BSACI. British Society for Allergy and Clinical Immunology. (1999) (2)
Important factors to consider for patients with community-acquired pneumonia. (2005) (2)
Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study (2022) (2)
Dupilumab (DPL) Efficacy in Patients With Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) with/without Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): SINUS-24, SINUS-52 Trials (2019) (2)
Is Sublingual Immunotherapy the Final Answer? Implications for the Allergist (2008) (2)
Prevalence of allergic conjunctivitis in Italian young man (1996) (2)
Cochrane Review: Sublingual immunotherapy for treating allergic conjunctivitis (2012) (2)
A Focus on Chronic Rhinosinusitis with Nasal Polyposis: Leaving Aside Endoscopic Surgery, a Step towards Biologic Therapies (2017) (2)
Changed allergy pattern in outpatients (1997) (2)
Impact of bronchiectasis on severe asthma: data from the “Severe Asthma Network Italy” (SANI) registry (2018) (2)
Antiallergic drugs and quality of life (2005) (2)
Validation of the Italian Version of the Test of Adherence to Inhalers (2020) (2)
Venom Immunotherapy and Aeroallergen Immunotherapy: How Do Their Outcomes Differ? (2022) (2)
Targeted therapy for allergic asthma: predicting and evaluating response to omalizumab (2007) (2)
Economic evaluation of sublingual immunotherapy versus symptomatic treatment in adults with pollen-induced respiratory allergy: the SPAI study. (2006) (2)
European Academy of Allergology and Clinical Immunology ‘EAACI’ guidelines for continuing medical education * (1997) (2)
FOOD ALLERGY AND DYSPEPSIA (1988) (2)
SEVERE ASTHMA: ONE DISEASE MANY DEFINITIONS (2019) (2)
Asthma management among allergists in Italy: results from a survey (2016) (2)
Cross-cultural adaptation and validation of the RhinAsthma Patient Perspective (RAPP) in Spanish. (2020) (2)
Specific immunotherapy with allergens: an important tool in the treatment of the allergic diseases (2012) (2)
Specific conjunctival challenge in polysensitized subjects (1997) (2)
Comorbid allergic rhinitis and asthma: important clinical considerations (2022) (2)
The ARIA approach of Value-Added Medicines: as-needed treatment in allergic rhinitis. (2022) (2)
When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation (2019) (2)
A11/264 – Global Asthma Physician & Patient (GAPP) survey: barriers to treatment – North American pediatric findings (2006) (2)
Terfenadine (single or associated) treatment of adverse reactions to foods. (1987) (2)
Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK‐air® longitudinal study (2022) (2)
Real‐world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities (2022) (2)
Patients' and physicians' perspectives on the burden and management of asthma: Results from the APPaRENT 2 study. (2022) (2)
Efficacy and Safety of High ICS Dose Fixed-Combination ICS/LABA/LAMA pMDI Compared with ICS/LABA and ICS/LABA + LAMA in Patients with Uncontrolled Asthma: The TRIGGER Study (2019) (2)
Dupilumab (DPL) Improves Upper and Lower Airway Outcomes in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) with Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): Pooled Results From SINUS-24, SINUS-52 Phase 3 Trials (2019) (2)
Evidence based treatment of allergic rhinitis (2007) (1)
Efficacy of sublingual immunotherapy (SLIT) in treating allergic conjunctivitis (AC). A Cochrane systematic review and meta-analysis (2009) (1)
Specific immunotherapy: still young after one century. (2005) (1)
Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air® approach (2023) (1)
Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy (2022) (1)
Very rapid improvement of extended nitric oxide parameters, associated with clinical and functional betterment, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) treated with Dupilumab. (2022) (1)
Clinical outcomes related to molecular allergy diagnosis (2019) (1)
Back to Basics in Asthma and COPD: Optimising the Patient Journey (2018) (1)
Inhaled triamcinolone and chronic obstructive pulmonary disease. (2001) (1)
World Allergy Forum Symposium: New Insights Into Immunotherapy for Allergic Disorders (2009) (1)
European medicines agency guideline for biological medicinal products: a further step for a safe use of biosimilars (2015) (1)
Normalization of Airflow Obstruction with Extra Fine Beclomethasone Dipropionate, Formoterol Fumarate, and Glycopyrronium Bromide (BDP/FF/GB) pMDI: A Post-Hoc Analysis of the TRIMARAN and TRIGGER Studies (2021) (1)
Role of leukotriene receptor antagonists in the management of mild-to-moderate asthma. (2001) (1)
Real-world data: how they can help to improve quality of care (2021) (1)
Sublingual Immunotherapy with Honeybee venom reduces large local reactions: a randomized, double blind controlled study (2007) (1)
Treatment of severe cold urticaria with associated cetirizine and zafirlukast (2003) (1)
CHAPTER 25 – SUBPOPULATIONS OF HUMAN T LYMPHOCYTES: FUNCTIONAL CHARACTERISTICS (1979) (1)
Erratum to: Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement (2017) (1)
Freedom to enjoy life – the ultimate goal in allergy management (2006) (1)
Comparative study between two immunoassays for detection of allergen-specific IgG4. (1991) (1)
Effect of extrafine medium strength (MS) ICS-containing triple therapy on exacerbations in asthmatics with persistent airflow limitation: A post-hoc analysis of the TRIMARAN study (2019) (1)
Epidemiology of rhinitis and conjunctivitis in athletes (2005) (1)
Correlation of serum vitamin D concentration with humoral‐specific IgG2 and IgG4 levels in high responders to immunotherapy with a 300 IR sublingual house dust mite tablet (2022) (1)
Epidemiology of lung function in a global severe asthma population (2019) (1)
Cromolyn's effects on the immune system. (1986) (1)
Asthma research and practice: a new journey begins (2015) (1)
Review of Desloratadine Data Using the ARIA Guidelines (2012) (1)
Systemic corticosteroids in asthma: A call to action from World Allergy Organization and Respiratory Effectiveness Group (2022) (1)
Recognising the long-term burden of short course oral corticosteroids (2021) (1)
The Present and Future of Allergen Immunotherapy in Personalized Medicine (2022) (1)
Levocetirizine in the treatment of allergic diseases (2009) (1)
Allergen Component Resolved Diagnostics in Multi-Sensitized Patients with Respiratory Symptoms (2010) (1)
Proteomics analysis of asthma biomarkers: proxima sub-study (2017) (1)
Occurrence of lymphocyte proliferative response to thyroglobulin and antithyroglobulin antibodies in normal individuals: lack of correlation with HLA (1987) (1)
A Global Survey of Blood Eosinophil Distribution in Severe Asthma Patients: Data from the International Severe Asthma Registry (ISAR) (2020) (1)
International Severe Asthma Registry (ISAR): The Story so Far (2019) (1)
Worldwide differences on the concept of control of asthma (2008) (1)
The ARIETTA study: baseline demographics in a real-world setting in patients with severe asthma (2017) (1)
3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD (2021) (1)
Oral, nasal and sublingual immunotherapy: do they work, are they safe? (2003) (1)
Assure-Csu: Resource Use and Economic Burden in Patients with Refractory Chronic Spontaneous/Idiopathic Urticaria in Italy (2016) (1)
Comparative Analysis of Indirect Costs Associated with Chronic Spontaneous/Idiopathic Urticaria-Results From The Assure-Csu Study In 7 Countries (2016) (1)
931 The impact of children's asthma and rhinitis on caregivers (2000) (1)
Poster 1001: ALLERGENIUS®: an expert system for the interpretation of allergen microarrays (2014) (1)
Correction to “ARIA guideline 2019: treatment of allergic rhinitis in the German health system” (2020) (1)
Nedocromil sodium and the immune response. (1993) (1)
Immune Response to Mycobacteria 4 Characterization of Immunocompetent Cells in Tuberculous Lesions of Humans (1)
Efficacy of Desloratadine in Persistent Allergic Rhinitis -- A GAtextsuperscript2LEN Study (2010) (1)
Perturbations of NK cell regulatory functions in respiratory allergic diseases (2007) (1)
Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study (2019) (1)
Glycoproteic nature of surface molecules of effector cells with lymphokine‐activated killer (LAK) activity. Evidence that T11, T8 or T3 molecules are not involved in tumor‐cell lysis by LAK effector T cells (1987) (1)
Sublingual immunotherapy: what lessons can we draw from recent studies? (2004) (1)
Cross-cultural adaptation and validation of the RhinAsthma Patient Perspective (RAPP) in the Polish population (2020) (1)
WAO-ARIA consensus on chronic cough – Part III: Management strategies in primary and cough-specialty care. Updates inCOVID-19 (2022) (1)
Assure-Csu: Assessing the Impact of Chronic Spontaneous / Idiopathic Urticaria on Work Productivity and Activity (2016) (1)
Mepolizumab improves lung function under real-world settings in REALITI-A study (2020) (1)
A2BCD: a concise guide for asthma management. (2023) (1)
Metanalisis of the efficacy of sublingual immunotherapy in asthma in pediatric patients, 3 to 18 years of age (2007) (1)
Current treatment strategies for seasonal allergic rhinitis: where are we heading? (2022) (1)
Nasal cytology as a reliable non-invasive procedure to phenotype patients with type 2 chronic rhinosinusitis with nasal polyps (2022) (1)
Immunotherapy – 2082. Long term prevention of asthma and rhinitis in children with atopic dermatitis four year after discontinuation of sublingual immunotherapy (2013) (1)
GAPP Italy: "A survey on asthma on Italian physicians and patients". (2010) (1)
New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases. (2017) (1)
MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis (2016) (1)
Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma (2020) (1)
Validation of the Italian version of the Test of Adherence to Inhalers (TAI). (2020) (1)
191 Kinetics of radiolabelled allergen administered by sublingual and oral route (1996) (1)
Effects of tetroxoprim and sulfadiazine on T lymphocyte proliferation and gamma-interferon production. (1989) (1)
An introduction to Current Opinion in Allergy and Clinical Immunology (2001) (1)
Chapter 2. Epidemiology of rhinitis and conjunctivitis in athletes (2005) (1)
Abnormalities of Immunocompetent Cells in Primary Biliary Cirrhosis (1982) (1)
Fexofenadine treatment reduces nasal congestion in persistent allergic rhinitis (2002) (1)
PRISE EN CHARGE DE LA RHINITE ALLERGIQUE GUIDE DE POCHE DE REFERENCE 2007 (2008) (1)
Prevalence of familial link in patients affected by chronic rhinosinusitis with nasal polyposis (2022) (1)
Erratum to: Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients? (2017) (1)
The Arietta Study: Exploring Severe Asthma Biomarkers in a Real-World Setting (2016) (1)
COPD SYMPTOMS, CIRCADIAN RHYTHM AND CLINICAL PHENOTYPES IN ITALIAN PATIENTS: BASELINE RESULTS OF THE STORICO COHORT OBSERVATIONAL STUDY (2018) (1)
Correction to: Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study (2019) (1)
Incidence of T cell subset imbalance in relatives of Graves’ disease patients (1984) (1)
Post marketing survey on the safety of sublingual immunotherapy in children below the age of 5 (2005) (1)
Re Letter to the editor re: Compalati E, Canonica GW. Efficacy and safety of rupatadine for allergic rhinoconjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. Curr Med Res Opin 2013 Jul 5. (2014) (1)
Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective: pan European patient survey (2021) (1)
"United Airways Disease" and Phenotypic Peculiarities of Respiratory Allergy in Immigrants (2009) (1)
Two screening methods for detection of specific IgE to inhalant allergens. Comparison with skin prick test and RAST. (1991) (1)
The year in review: The best of 2016 in the Annals. (2017) (1)
An Update on Sublingual Immunotherapy (2005) (1)
Development and validation of an electronic daily control score for asthma (e-DASTHMA): a real-world direct patient data study. (2023) (1)
Side effects of antituberculosis treatment. (2001) (0)
Prevalence and impact of rhinitis, sleep disordered breathing and OSA in asthmatic patients (2013) (0)
BIOSIMILARS DEVELOPMENT – ECONOMIC POINT OF VIEW (2015) (0)
Sleep Apnea Risk in Patients With Asthma With or Without Comorbid Rhinitis (2014) (0)
ES10 The United Airways Disease (2014) (0)
Minimal Persistent Inflammation and Antihistamines (2003) (0)
CLINICAL DATA 15 CLINICAL EXPERIENCES IN CHILDREN (2000) (0)
Evolution in Endoscopic Sinus Surgery: The Adjuvant Role of Reboot Surgery in Patients with Uncontrolled Nasal Symptoms of Eosinophilic Granulomatosis with Polyangiitis (2023) (0)
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis (2022) (0)
Hairy T-cell leukemia: a case report. (1983) (0)
31 Mizolastine in vitro on human immunocompetent and airway cells: Evidence for safety and additional property (2000) (0)
PRS62 Applying Multiple Criteria Decision Analysis (MCDA) to Assess the VALUE of Budesonide-Formoterol Maintenance and Reliever Therapy in Asthma- an Empirical Case Study (2020) (0)
[Biopsies in pneumology: pleuroscopies-biopsies]. (1975) (0)
Treatment of allergic rhinitis using mobile technology with real world data (2018) (0)
Relationship between quality of life related to chronic cough and asthma level of control; a pilot study (2007) (0)
Editorial introductions. (2016) (0)
Highlights on the EAACI–WAO Congress 2013 (2013) (0)
Clinical Evolution and Quality of Life in Clinically Based COPD Chronic Bronchitic and Emphysematous Phenotypes: Results from the 1-Year Follow-Up of the STORICO Italian Observational Study (2021) (0)
[ICAM-1 and allergic inflammation]. (1997) (0)
Food-pollen cross-reactivity in oral allergy syndrome and rhinitis (2003) (0)
Serum CTLA-4 and IL-10 in Hymenoptera Venom Immunotherapy. The Immunological Equivalence of Different Induction Protocols (2011) (0)
A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma (2022) (0)
In the UnitedStates,wesupportthe approachrecommended by the US Rhinitis Practice Parameters, which recommends NAH as first-line therapy. 2 It is our unanimous clinical experience that these medications are useful as a primary therapy. (2016) (0)
New Insights into Allergen-Specific Immunotherapy in Rhinitis and Asthma (2009) (0)
Do Asthmatic Patients and Their Physicians Agree on the Presence and Severity of Allergic Rhinitis? (2015) (0)
Evaluation Of Quality Of Life In Patients With Allergic Rhinitis (2009) (0)
Original article Disability in COPD and its relationship to clinical and patient-reported outcomes (2011) (0)
Care for Patients with Type-2 Chronic Rhinosinusitis (2023) (0)
Low Levels of Cytokines and Growth Factors in Serum of Allergic and Non-Allergic Top Atletes (2011) (0)
COVID-19 Pandemic—Allergen-specific Immunotherapy Positioning in Respiratory Allergy (2020) (0)
Allergic rhinitis and its impact on asthma (ARIA) in Greece: Integrated care pathways for predictive medicine across the life cycle (2018) (0)
Effect of triple therapy with extra-fine BDP/FF/GB pMDI during seasonal peaks of asthma exacerbations. A post-hoc analysis of the TRIMARAN and TRIGGER studies (2020) (0)
Efficacy And Safety Of Fexofenadine In Allergic Rhinitis (AR): A Metanalysis (2009) (0)
Current Opinion in Allergy and Clinical Immunology: Editorial introductions (2009) (0)
In vitro immune response to misoprostol (synthetic prostaglandin) (1991) (0)
Reversal of Italian Reimbursement Restriction on Antihistamines is Associated with Better Clinical Outcomes among Children with Allergy-Induced Asthma (2006) (0)
EAACI CME Accreditation Committee. Continuing Medical Education: an international reality (2005) (0)
Neither sex nor overweight are risk factors for having asthma symptoms in adolescent population of Argentina (2007) (0)
The use of Emerging Technologies in Allergen Immunotherapy Management (2017) (0)
Contents Vol. 153, 2010 (2010) (0)
EUFOREA treatment algorithm for allergic rhinitis (2020) (0)
Letter to the Editor (2014) (0)
Use, Abuse, and Misuse of Nasal Medications: Real-Life Survey on Community Pharmacist’s Perceptions (2023) (0)
Validation of the GA(2)LEN chamber for trials in allergy Innovation of a mobile allergen exposure chamber Allergy and Asthma (0)
The Prevalence of Immediate Hypersensitivity Reactions to the BNT162b2 mRNA Vaccine against SARS-CoV-2: Data from the Vaccination Campaign in a Large Academic Hospital (2023) (0)
Late Breaking Abstract - International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A (2021) (0)
Biomarker Relatability in the International Severe Asthma Registry (2020) (0)
205 Allergy Training and Immunotherapy in Latin America: How Survey-Results Lead to a Regional Overview (2012) (0)
Regulation of HLA antigen expression in phagocytes treated with mycobacteria (1997) (0)
Pirenzepine treatment in urticaria-angioedema syndrome caused by adverse reactions to foods. (1989) (0)
The Prescribing Practice for COPD: Relationship to Circadian Rhythm, Disease Severity, and Clinical Phenotype in the STORICO Observational Study (2022) (0)
92 Serum CTLA-4 AND IL-10 in Hymenoptera Venom Immunotherapy: Equivalence of Different Induction Regimens (2012) (0)
Adding a biologic to allergen immunotherapy increases treatment efficacy (2023) (0)
Problem of nonresponse to allergen immunotherapy (2019) (0)
Detection of CC16 in sputum: A potential biomarker of COPD small airways damage (2005) (0)
T regulatory cells: Immunomodulation by budesonide and formoterol on COPD patients (2015) (0)
Normalisation of airflow limitation in asthma: Post‐hoc analyses of TRIMARAN and TRIGGER (2022) (0)
A troublesome diagnosis of Churg Strauss Syndrome (2007) (0)
DUPILUMAB REDUCES SEVERE OUTPATIENT ASTHMA EXACERBATIONS, CUMULATIVE DOSE, AND TOTAL NUMBER OF DAYS OF SYSTEMIC CORTICOSTEROID USE AMONG PATIENTS WITH MODERATE-TO-SEVERE TYPE-2 ASTHMA (2020) (0)
Faculty Opinions recommendation of Benefit of the basophil activation test in deciding when to reintroduce cow's milk in allergic children. (2011) (0)
Evaluation of Fc gamma-positive T lymphocytes in Graves' disease: Preliminary report (1981) (0)
276 A 4-Year Follow-up in Children With Moderate/Severe Asthma after Withdrawal 1 Year Omalizumab Treatment (2012) (0)
Side effects of antituberculous treatment (2001) (0)
Gender differences in patients with severe asthma in real-life setting: data from the Severe Asthma Network in Italy (SANI) registry (2019) (0)
Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study (2020) (0)
Oral corticosteroid (OCS) risk predictor for Type II Diabetes in asthma (2022) (0)
Clinical Remission Achievement in Severe Asthma Following Mepolizumab Treatment: Results From the REALITI-A Study at 2 Years (2023) (0)
Issue Information (2021) (0)
IL4 and IL13 bind to different types of functional IL4/IL13 receptors on human lung fibroblasts (1998) (0)
Editorial introductions. (2017) (0)
PRS45 Obstructive Airway Diseases: Real Clinical Practice from the Large Italian Administrative Database of Fondazione Ricerca E Salute (RES) (2020) (0)
Impact of early management of the allergy march (2001) (0)
Association Between T2-related Comorbidities and Effectiveness of Biologics in Adult Patients From the International Severe Asthma Registry (2023) (0)
Organic Cation Transporters (OCT) Expression By Human Airway Epithelial Cells, Fibroblasts And Smooth Muscle Cells (2010) (0)
Subject Index Vol. 155, 2011 (2011) (0)
Assessing Health-Utility Values for Chronic Spontaneous/Idiopathic Urticaria In Real-World Using The EQ-5D: Results From Assure-Csu Study (2016) (0)
The Influence of Environment on Respiratory Allergy. A Survey on Immigrants to Italy (2011) (0)
Introduction (2002) (0)
Dupilumab Efficacy in Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma by Baseline IgE and Thymus and Activation Regulated Chemokine Levels from the Pooled Population of the SINUS-24 and SINUS-52 Phase 3 Trials (2020) (0)
National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study (2022) (0)
From Symptom Control to Disease Management (2005) (0)
Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study (2017) (0)
The Allergic March Resolved At Allergen Component Level (2012) (0)
Biologic Responders and Super-responders in the International Severe Asthma Registry (2023) (0)
Lower respiratory infections: observational study in Genoa (2000) (0)
Serum GAL3 predict response in omalizumab-treated patients with severe allergic asthma: the PROXIMA study (2018) (0)
437 ICAM-1 expression and regulation on 3 epithelial cells: Relevance for allergic inflammation (1996) (0)
Polyethylene Glycol and Polysorbate 80 Skin Tests in the Context of an Allergic Risk Assessment for Hypersensitivity Reactions to Anti-SARS-CoV-2 mRNA Vaccines (2023) (0)
Author response for "Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies" (2021) (0)
Asthma symptoms and lung function measurements in subjects with seasonal intermittent asthma (SIA) (2002) (0)
Asthma management in a specialist setting: Results of a national survey (2016) (0)
Phenotypic and functional T cell abnormalities in children with IDDM (1984) (0)
Oral Allergy Syndrome and United Airways Disease. Is there a functional connection (2011) (0)
IS1-2 What Are the Strategies for Preventing and Curing Allergy?(IS1 What Are the Strategies for Preventing and Curing Allergy?) (2008) (0)
CU-QoL: A new specific quality of life questionnaire for patients with chronic urticaria (2005) (0)
PRS24 The CROSS-Coverage Effect of Dupilumab in Treating Coexisting Type 2 Inflammatory Diseases on the Italian National Health Service Expenditure. (2020) (0)
50 The Allergic March Resolved at Allergen Component Level (2012) (0)
IL10 Specific Immunotherapy for Respiratory Allergy : State of the Art According to Evidences (2008) (0)
Grass pollen and asthma. Author' reply (1992) (0)
EffectsExpression and Proinflammatory CD40 on Adult Human Airway Epithelial (2013) (0)
1044 CD40 triggering: A functional role on human airway epithelial cells (2000) (0)
[Real-world analysis of obstructive respiratory tract disorders: characterization, health care and costs.] (2021) (0)
Asthma control and Quality of Life in asthmatic patients (2007) (0)
Immune response to Rotavirus in the pathogenesis of celiac disease: molecular effects of anti-VP7 viral protein antibodies on intestinal epithelial cells using a gene array approach (2007) (0)
COVID-19-vaccination in patients receiving allergen immunotherapy (AIT) or biologics - EAACI recommendations (2021) (0)
Effect of Medium ICS Dose Fixed Combination Extra Fine Beclomethasone Dipropionate, Formoterol Fumarate, and Glycopyrronium Bromide (BDP/FF/GB) pMDI on Lung Function in Asthmatics with Persistent Airflow Limitation (PAL): A Post-Hoc Analysis of the Trimaran Study (2020) (0)
Impact of COVID-19 in allergen immunotherapy: An Italian survey. (2022) (0)
This information is current as Differentiation Propionate During Lung Myofibroblastic Inhaled Corticosteroid Fluticasone Novel Anti-inflammatory Effects of the (2001) (0)
Contents Vol. 155, 2011 (2011) (0)
Latin American Guideline on the Diagnosis and Treatment of Ocular Allergy - On behalf of the Latin American Society of Allergy, Asthma and Immunology (SLAAI) (2022) (0)
Drug allergy and quality of life (2007) (0)
Quantitative assessment of the adherence to allergoid sublingual immunotherapy in patients with house dust mite sensitization: The INSIT study☆ (2004) (0)
Safety of subcutaneous immunotherapy for allergic respiratory diseases: a prospective study (2007) (0)
ALLERGY AND AIRWAY DISEASES (2022) (0)
In Memoriam - A Tribute to Carlos E. Baena-Cagnani (2015) (0)
Sublingual Immunotherapy (SLIT) for House Dust Mites (HDM) in respiratory allergy: update of metanalysis results (2009) (0)
PRS50 Defining Type 2 Asthma and Patients Eligible to Dupilumab in Italy: A Biomarker-Based Analysis (2020) (0)
ARIA suggested drugs for allergic rhinitis and Quality of Life. A GA2LEN review (2007) (0)
[Our experience in the treatment of bronchial asthma and asthmatic bronchitis with salbutamol]. (1976) (0)
EffectsCells: Expression and Proinflammatory CD40 on Adult Human Airway Epithelial (2004) (0)
Utility of fast in food allergy: a case report (2007) (0)
Care about patients with chronic rhinosinusitis and type-2 inflammation (2020) (0)
New Insights in Airway Remodeling (2007) (0)
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1b molecules after bacterial phagocytosis (1998) (0)
Section 3. A Discussion of Flexible Dosing and Patient-Centered Therapy: Highlights of the Asthma Summit 2009: Beyond the Guidelines (2010) (0)
WJS2 WAO SLIT Position Paper update (2014) (0)
New Rush Schedule for Cotrimoxazole Desensitization : A Report of 2 Cases (2018) (0)
EVS3-3 Allergic Rhinitis : From Evidence to Guidelines (2008) (0)
The immunological events leading to the "in vitro" response to PPD. (1987) (0)
Contents, Vol. 96, 1991 (1991) (0)
Contents Vol. 160, 2013 (2013) (0)
Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in patients with severe asthma eligible for both. (2023) (0)
Comparison of evidence of treatment effects in randomized and nonrandomized studies on allergen immunotherapy. (2023) (0)
Validation and Qualification of Biomarkers and Their Translation Into Pathway-Specific Diagnostic Tests (2019) (0)
New approaches to the design of sublingual immunotherapy clinical trials (2011) (0)
Does allergic rhinosinusitis exist (2003) (0)
Overview of novel therapeutic targets for asthma and chronic obstructive pulmonary disease (2005) (0)
Management of allergic rhinitis symptoms in the pharmacy Pocket guide 2022 (2022) (0)
Improvement of daily allergy control by sublingual immunotherapy: A MASK-air® study. (2023) (0)
Patient‐reported outcome measures in birch pollen allergic patients treated with sublingual immunotherapy reflect real life (2022) (0)
RMHP_A_211321 43..53 (2020) (0)
Comparison of the Congestion Quantifier 5- & 7-item Scales to Monitor Nasal Congestion (2008) (0)
Faculty Opinions recommendation of Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. (2012) (0)
Cut-off values of MASK-air® Patient-Reported Outcome Measures (PROMs). (2022) (0)
LATE-BREAKING ABSTRACT: Intra-day symptoms fluctuations: STORICO, observational study on the characterization of 24-hour symptoms in COPD patients (2016) (0)
Administration of sublingual vaccines. (2008) (0)
Patient-centred digital biomarkers for allergic respiratory diseases and asthma: the ARIA-EAACI approach. (2023) (0)
Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis (2023) (0)
List of Contributors (2019) (0)
SNOT-22 items and association with objective measures in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from SINUS-24 and SINUS-52 trials (2021) (0)
One year of mepolizumab in severe asthma in Italy: efficacy and safety (2019) (0)
Dupilumab treatment effects are observed after the first dose across atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps: Data from Phase 3 SOLO 1 & 2, LIBERTY ASTHMA QUEST, and SINUS-52 Studies (2020) (0)
Sublingual immunotherapy: recent advances. (2013) (0)
[Executive Summary of ARIA 2019: Integrated care pathways for allergic rhinitis in Argentina, Spain and Mexico]. (2019) (0)
A new questionnaire for food allergy (2007) (0)
ARIA 2016 executive summary: Integrated care pathways for predictive, preventive and personalized medicine across the life cycle (2018) (0)
Intranasal corticosteroid and antihistamine combinations in the treatment of allergic rhinitis: the role of the novel formulation olopatadine/mometasone furoate. (2023) (0)
Acknowledgement to Referees (2017) (0)
grading SLIT jaci 2013 (2013) (0)
Letter to the editorThe authors' reply (2006) (0)
Chapter 9. Prevention: educational issues and recommendations for early recognition (2005) (0)
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study (2022) (0)
Sublingual immunotherapy. (2003) (0)
Quantitative determination of fibronectin (FN): evaluation of immunoturbidimetric and rate nephelometric techniques for FN assay in the different biologic materials. (1995) (0)
Exploration of Asthma & Allergy, where science, evidence, and vision can improve clinical practice (2022) (0)
The Relationship Between Asthma Control, Impact Of Co-morbid Rhinitis And Health Related Quality Of Life: A Real Life Study. (2009) (0)
Effectiveness of pulmonary rehabilitation programs on persistent asthma. (2018) (0)
LOCAL ROUTES FOR ALLERGEN IMMUNOTHERAPY (1999) (0)
Oral routes for immunotherapy: clinical efficacy and kinetics of the allergen. (1997) (0)
Cytokines and airways: recent insights and therapeutic implications. (1998) (0)
Contents, Vol. 71, 1983 (1983) (0)
Clinical efficacy and CXCR3 - CCR3 modulation by parietaria immunotherapy (2007) (0)
Commentary Impact of rhinitis on airway inflammation: biological and therapeutic implications (2001) (0)
Asthma management in real life; preliminary data from CPD-ARGA project (2007) (0)
Artificial intelligence processing electronic health records to identify commonalities and comorbidities cluster at Immuno Center Humanitas (2022) (0)
Editorial introductions. (2020) (0)
Faculty Opinions recommendation of Synbiotics reduce allergen-induced T-helper 2 response and improve peak expiratory flow in allergic asthmatics. (2010) (0)
One-Year Evolution of Symptoms and Health Status of the COPD Multi-Dimensional Phenotypes: Results from the Follow-Up of the STORICO Observational Study (2021) (0)
Lymphokine Production and Functional Activities of T Cell Clones From Thyroid Gland of Hashimoto’s Thyroiditis (1987) (0)
Desensitization Protocols for Anti-SARS-CoV-2 Vaccines in Patients with High Risk of Allergic Reactions (2023) (0)
Sublingual Immunotherapy: Recent (2013) (0)
Biomarker relatability in the International Severe Asthma Network (2020) (0)
Systematic Review of Real-World Effectiveness and Safety Studies of Mepolizumab in Treating Severe Eosinophilic Asthma (0)
Efficacy of allergen immunotherapy in hay fever (2018) (0)
A 4 years follow up in children with moderate/severe asthma after discontinuation of 1 year treatment with omalizumab (2011) (0)
Cluster analysis according to biomarker profile differentiates clinical subgroups in the International Severe Asthma Registry (ISAR) (2020) (0)
Patient's Adherence and Compliance and Quality of Life During/After VIT (2022) (0)
Efficacy of mometasone furoate nasal spray-MFNS- in the treatment of allergic rhinitis. Meta-analysis of randomized controlled trials (2007) (0)
Expression of Cell Adhesion Molecules in Allergic Disorders of the Eye (2020) (0)
Natural Killer (NK) Cell Subsets in Allergic Patients (2006) (0)
Correction: Digital Coaching Using Smart Inhaler Technology to Improve Asthma Management in Patients With Asthma in Italy: Community-Based Study (2022) (0)
Adherence in allergen immunotherapy: Current situation and future implications (2022) (0)
Long-term comparison of the efficacy of the efficacy of sublingual immunotherapy vs inhaled budesonide in grass-induced asthma (2007) (0)
Long-term comparison of the efficacy of adding sublingual immunotherapy or montelukast in birch-induced asthma (2007) (0)
Much Immunotherapy – but Other Topics, too (2004) (0)
The World Allergy Organization Today (2008) (0)
The world allergy organization today. (2008) (0)
Development and Validation of Nasal Polyposis Quality of Life Questionnaire (NPQ) (2020) (0)
Food allergy and digestive pathology: pathophysiologic, diagnostic and therapeutic aspects. (1990) (0)
Effectiveness of initiating biologics in severe asthma patients with high steroid exposure (2022) (0)
[ARIA (Allergic Rhinitis and its Impact on Asthma) 2019. Treatments for allergic rhinitis - Italy.] (2021) (0)
International, prospective study of mepolizumab in severe asthma: REALITI-A at 2yrs (2022) (0)
State of World Allergy Report 2008: Allergy and Chronic Respiratory Diseases (2008) (0)
The Non Allergic Component Of Allergic Rhinitis (2009) (0)
Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting (2017) (0)
Recognition, prevention, and treatment of adverse effects associated with sublingual immunotherapy (2020) (0)
Physician and Patient Perspectives on Treatment Adherence in Asthma Management: Results From Apparent 1&2 (2023) (0)
Long-Term Continuous Antiallergic Treatment Reduces Symptoms and Controls Allergic Inflammation Better than Symptomatic Treatment (2002) (0)
Omalizumab decreases medical resource utilisation in patients with severe allergic asthma in an Italian real-life setting (2017) (0)
Is asthma control more than just an absence of symptoms? An expert consensus statement. (2022) (0)
ENGLISH VERSION: INTEGRATED CARE PATHWAYS FOR PREDICTIVE MEDICINE ACROSS THE LIFE CYCLE (ARIA – 2016 EXECUTIVE SUMMARY) (2017) (0)
Effects of Levocetirizine on Symptoms and Quality of Life in Persistent Allergic Rhinitis and Comorbid Asthma (2006) (0)
New Biologicals in Respiratory Allergies (2018) (0)
Iconographies supplémentaires de l'article : International consensus on allergy immunotherapy (2015) (0)
NONINJECTIVE IMMUNOTHERAPY : PRESENT KNOWLEDGE AND EXPERIMENTAL EVIDENCE (1999) (0)
Adhesion molecules in allergy. (1997) (0)
Manifesto on inhaled triple therapy in asthma: an Interasma (Global Asthma Association – GAA) document (2021) (0)
The effects of disease cross-coverage by dupilumab on the costs sustained by the Italian National Health Service (2020) (0)
S27 Effect of high ICS dose fixed combination extrafine beclomethasone dipropionate, formoterol fumarate, and glycopyrronium (BDP/FF/G) pMDI on asthma control in patients with persistent airflow limitation (PAL): a post-hoc analysis of the TRIGGER study (2021) (0)
The role of pneumococcal vaccine: Review article (2018) (0)
In vitro immune response to rosaprostol (prostaglandinic analogue) (1989) (0)
Editorial introductions. (2017) (0)
Serum Ctla-4 And Il-10 In Hymenoptera Venom Immunotherapy: Equivalence Of Different Induction Regimens (2010) (0)
Altered composition of airway basement membranes in COPD (2011) (0)
Allergic rhinitis and asthma survey: clinical and psychological perspectives (2007) (0)
Subject Index Vol. 153, 2010 (2010) (0)
Efficacy and safety of levocetirizine 5mg as continuous or on-demand treatment for persistent allergic rhinitis over 6 months (2007) (0)
Cross-Country Comparison of Demographic and Clinical Characteristics of Patients Managed in Severe Asthma Services Across UK, USA, Australia, South Korea, and Italy (2019) (0)
Editorial introductions. (2018) (0)
PRS72 - A COST ESTIMATION OF MANAGEMENT OF ALLERGIC ASTHMA IN ITALY (2018) (0)
Current advances in house dust mite allergen immunotherapy (AIT): Routes of administration, biomarkers and molecular allergen profiling. (2023) (0)
Editorial introductions. (2019) (0)
Acknowledgement to reviewers 2009 (2010) (0)
PRS67 GENDER DIFFERENCES IN ASTHMA PERCEPTION AND IMPACT ON QUALITY OF LIFE: A POST-HOC ANALYSIS OF THE PROXIMA OBSERVATIONAL STUDY (2019) (0)
Continuing medical education. The point of view of asthmatic patients at the beginning of a mandatory CME system. (2004) (0)
Prof. Mario Sánchez Borges: An enduring legacy and a life well-lived. (2021) (0)
Editorial to the ASTHMA Issue. (2019) (0)
Correction to: Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride (2022) (0)
Early increase in serum specific IgG2 upon allergen immunotherapy with a 300 IR sublingual house dust mite tablet. (2023) (0)
409 Oral Allergy Syndrome and United Airways Disease: Is There a Functional Connection? (2012) (0)
Preface - a new section for our Journal - 'Perspectives' (2009) (0)
Allergen Immunotherapy: Current State and Ways Forward (2018) (0)
OCS Tapering Delphi (2019) (0)
Immunotherapy can change the natural history of respiratory allergy (2013) (0)
A Charter to Fundamentally Change the Role of Oral Corticosteroids in the Management of Asthma (2023) (0)
Systemic anaphylaxis induced by lupin ingestion: two case reports (2007) (0)
Evaluation of second generation antihistamines following a 2 or 4-weeks treatment by means of a pooled responder analysis in patients suffering from seasonal allergic rhinitis (2008) (0)
Contents Vol. 165, 2014 (2015) (0)
Prevalence and Severity of Asthma Symptoms in Adult Population of Northern Argentina (2009) (0)
Oxygen saturation measurement in obstructive outpatient: an useful tool for exacerbations management in GPs setting? (2007) (0)
World Allergy Forum Symposium: The Application of Monoclonal Therapies and Therapeutics to Asthma and Allergy (2008) (0)
Acknowledgement to reviewers 2009 (2009) (0)
Allergic Respiratory Disorders in Athletes (2005) (0)
Cost-Effectiveness of Sublingual Specific Immuno-Therapy Versus Current Symptomatic Treatments in Adults with Allergic Rhinitis and Asthma, in the Societal Perspective (2006) (0)
International Conference on Allergic Rhinitis in Childhood: Preface (1999) (0)
Dupilumab Improves Upper and Lower Airway Outcome Measures in Patients With CRSwNP With NSAID-ERD: Pooled Results from the SINUS-24 and SINUS-52 Phase 3 Trials (2020) (0)
373 Alteration of Smell in Patients with Persistent Allergic Rhinitis (2012) (0)
T-LYMPHOCYTE ACTIVATION AND ALLERGY (1988) (0)
Prevention: educational issues and recommendations for early recognition (2005) (0)
Late Breaking Abstract - BENRALIZUMAB IN SEVERE ASTHMA: PRELIMINARY RESULTS FROM THE ITALIAN ANANKE STUDY (2020) (0)
Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps (2022) (0)
Legends of allergy and immunology: Lorenzo Moretta—Unfolding the mysteries of NK cells and much more (2022) (0)
Treatment of infected severe atopic dermatitis and common variable immunodeficiency with endovenous high dose immunoglobulines (HdIVIg): a case report (2007) (0)
Modulation of NK receptors by budesonide and/or formoterol in healthy volunteers and COPD patients (2011) (0)
The Use of Molecular Allergy Diagnosis in Anaphylaxis: a Literature Review (2019) (0)
PROTEOMICS – Clinical Applications Table of Contents (2015) (0)
Personalized medicine for allergy treatment: AIT still a unique and unmatched model (2020) (0)
Faculty Opinions recommendation of Depigmented-polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients. (2013) (0)
Human T Cell Ia Antigens Defined by Monoclonal Antibodies (1984) (0)
Syddansk Universitet Validation of the GA ( 2 ) LEN chamber for trials in allergy Innovation of a mobile allergen exposure chamber (0)
Cross-Cultural Validation of the Short Version of the Questionnaire of Olfactory Disorders—Negative Statements into Italian: Towards Personalized Patient Care (2022) (0)
Letter to the editor (1987) (0)
Specific immunotherapy for allergic respiratory diseases: evidence based evaluation (2007) (0)
Latex Allergy and Occupational Exposure: The Patient's Perspective. (2018) (0)
Allergy Training and Immunotherapy in Latin America: How Survey-Results Lead to a Regional Overview (2012) (0)
Development and Validation of an Electronic Daily Control Score for Asthma (e-DASTHMA) (2022) (0)

This paper list is powered by the following services:

Other Resources About Giorgio Walter Canonica

en.wikipedia.org

What Schools Are Affiliated With Giorgio Walter Canonica?

Giorgio Walter Canonica is affiliated with the following schools:

Giorgio Walter Canonica's Academic­Influence.com Rankings